[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Instrumentation Laboratory Co.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":136},{"warningLetters":4,"total":135},[5,32,52,72,91,114],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":30,"action_taken_date":31,"medical_device_id":19,"response_letter_date":19},1057,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-02-18T05:00:00Z\">02\u002F18\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-02-10T05:00:00Z\">02\u002F10\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fabr-laboratory-llc-696872-02102025\">ABR Laboratory LLC\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceutical\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-42\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Jorge D. Abraldes\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>ABR Laboratory LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>450 N Park Rd, Suite 303\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hollywood\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33021-6917\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-42\u003C\u002Fp>\u003Cp>February 10, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Abraldes:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your contract testing laboratory, ABR Laboratory LLC., FEI 3020570829, located at 450 North Park Road, Suite 303, Hollywood, FL 33021-6917, from September 9 to 13, 2024.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, the drug products you tested are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your September 29, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish and document the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm is a contract testing lab that analyzes drugs for your customers. You did not use a suitable method to test your client’s over-the-counter (OTC) drug products. For example, your method was not verified to be equivalent or better than the United States Pharmacopeia (USP) method used to test multiple OTC) drug products for potential microbial contamination. Your method for Plate Count \u003Cstrong>(b)(4)\u003C\u002Fstrong> growth media is different in composition to the Soybean-Casein Digest Agar required for plate count methods by USP&lt;61&gt; Microbiological Examination of Nonsterile Products: Microbial Enumeration Tests. You have not demonstrated your method is equivalent or better than the USP&lt;61&gt; compendial method. Additionally, you failed to perform method suitability for the microbial testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> OTC drug products. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product is intended for \u003Cstrong>(b)(4)\u003C\u002Fstrong> symptoms in children.\u003C\u002Fp>\u003Cp>Method suitability testing ensures the method can reliably determine the presence of microbial growth in the drug product. Without evaluating the validity of methods, you lack assurance that the data provided to customers was an accurate reflection of pharmaceutical drug product quality and safety.\u003C\u002Fp>\u003Cp>In your response you state you “have initiated a comprehensive validation of Test Method STP-002 Microbiological Testing of Raw Materials and Products” and “will conduct a suitability test for each product category.”\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide sufficient information to demonstrate that your methods are equivalent or better than the applicable USP compendial methods and suitable for their intended use. In addition, you state you will develop methods for each drug category; however, you do not provide data supporting your method for each product category is suitable for each individual drug product.\u003C\u002Fp>\u003Cp>\u003Cstrong>Responsibilities of Contract Testing Lab\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA considers contractors as extensions of the manufacturer’s own facility. Your failure to comply with CGMP may affect the quality, safety, and efficacy of the drugs you test for your clients. It is essential that you understand your responsibility to operate in full compliance with CGMP, and that you inform all your customers of any out-of-specification (OOS) results or significant problems encountered during the testing of these drugs.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>A retrospective review to determine the scope and the impact of the violation. The review should include a procedure to re-test drug product potentially affected by the violation and a procedure that details steps you will take in the case previously negative results are shown to be positive for microbial contamination, including notifying your customers.\u003C\u002Fli>\u003Cli>Updated procedures documenting how the suitability of all test methods will be determined, when method verification and validation occur, and corresponding training records.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to investigate out-of-range deviations in temperature and humidity readings in your laboratory equipment. For example, your 2 - 8°C refrigerator was out of range for more than 24 hours reaching temperatures of up to 17.4°C. This refrigerator houses the reference microorganisms used in your growth promotion tests. This deviation was not identified or investigated. Storing of reference microorganisms outside of their acceptable range compromises their ability to grow, thereby undermining their value as reference organisms and the accuracy of the results.\u003C\u002Fp>\u003Cp>In your response, you state you will update your relevant procedures. You also commit to implementing a real-time monitoring system to alert staff of any temperature deviations.\u003C\u002Fp>\u003Cp>Your response is inadequate. You fail to investigate the deviation to determine the scope and potential impact to the accuracy of your test results and you fail to identify a root cause to correct and prevent recurrence. You also do not commit to evaluating other laboratory and manufacturing equipment and their related procedures to ensure deviations are identified and investigated.\u003C\u002Fp>\u003Cp>In response to this letter, provide a comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, corrective action and preventive action effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm; you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3020570829 and ATTN: Carlos Gonzalez.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nReference #:\n\n320-25-42\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Jorge D. Abraldes\n\nRecipient Title\n\nCEO\n\nABR Laboratory LLC\n\n450 N Park Rd, Suite 303\n\nHollywood, FL 33021-6917\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-42\nFebruary 10, 2025\nDear Mr. Abraldes:\nThe U.S. Food and Drug Administration (FDA) inspected your contract testing laboratory, ABR Laboratory LLC., FEI 3020570829, located at 450 North Park Road, Suite 303, Hollywood, FL 33021-6917, from September 9 to 13, 2024.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, the drug products you tested are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your September 29, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to establish and document the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e)).\nYour firm is a contract testing lab that analyzes drugs for your customers. You did not use a suitable method to test your client’s over-the-counter (OTC) drug products. For example, your method was not verified to be equivalent or better than the United States Pharmacopeia (USP) method used to test multiple OTC) drug products for potential microbial contamination. Your method for Plate Count (b)(4) growth media is different in composition to the Soybean-Casein Digest Agar required for plate count methods by USP\u003C61> Microbiological Examination of Nonsterile Products: Microbial Enumeration Tests. You have not demonstrated your method is equivalent or better than the USP\u003C61> compendial method. Additionally, you failed to perform method suitability for the microbial testing of (b)(4) and (b)(4) OTC drug products. The (b)(4) drug product is intended for (b)(4) symptoms in children.\nMethod suitability testing ensures the method can reliably determine the presence of microbial growth in the drug product. Without evaluating the validity of methods, you lack assurance that the data provided to customers was an accurate reflection of pharmaceutical drug product quality and safety.\nIn your response you state you “have initiated a comprehensive validation of Test Method STP-002 Microbiological Testing of Raw Materials and Products” and “will conduct a suitability test for each product category.”\nYour response is inadequate. You do not provide sufficient information to demonstrate that your methods are equivalent or better than the applicable USP compendial methods and suitable for their intended use. In addition, you state you will develop methods for each drug category; however, you do not provide data supporting your method for each product category is suitable for each individual drug product.\nResponsibilities of Contract Testing Lab\nFDA considers contractors as extensions of the manufacturer’s own facility. Your failure to comply with CGMP may affect the quality, safety, and efficacy of the drugs you test for your clients. It is essential that you understand your responsibility to operate in full compliance with CGMP, and that you inform all your customers of any out-of-specification (OOS) results or significant problems encountered during the testing of these drugs.\nIn response to this letter, provide:\nA comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nA retrospective review to determine the scope and the impact of the violation. The review should include a procedure to re-test drug product potentially affected by the violation and a procedure that details steps you will take in the case previously negative results are shown to be positive for microbial contamination, including notifying your customers.\nUpdated procedures documenting how the suitability of all test methods will be determined, when method verification and validation occur, and corresponding training records.\n2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nYou failed to investigate out-of-range deviations in temperature and humidity readings in your laboratory equipment. For example, your 2 - 8°C refrigerator was out of range for more than 24 hours reaching temperatures of up to 17.4°C. This refrigerator houses the reference microorganisms used in your growth promotion tests. This deviation was not identified or investigated. Storing of reference microorganisms outside of their acceptable range compromises their ability to grow, thereby undermining their value as reference organisms and the accuracy of the results.\nIn your response, you state you will update your relevant procedures. You also commit to implementing a real-time monitoring system to alert staff of any temperature deviations.\nYour response is inadequate. You fail to investigate the deviation to determine the scope and potential impact to the accuracy of your test results and you fail to identify a root cause to correct and prevent recurrence. You also do not commit to evaluating other laboratory and manufacturing equipment and their related procedures to ensure deviations are identified and investigated.\nIn response to this letter, provide a comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, corrective action and preventive action effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm; you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3020570829 and ATTN: Carlos Gonzalez.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","ABR Laboratory LLC","abr-laboratory-llc-696872-02102025","2026-08-18T06:42:28.856152+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fabr-laboratory-llc-696872-02102025","2026-10-26T08:07:48.977815+00:00","Warning Letter","Issued","2025-02-18","696872","Drugs","Mr. Jorge D. Abraldes","2026-08-19T17:01:12.396+00:00","Via Email","320-25-42","2025-02-10",{"id":33,"raw":34,"subject":12,"body_html":38,"body_text":39,"firm_name":40,"letter_id":41,"created_at":42,"fei_number":19,"letter_url":43,"updated_at":44,"action_type":22,"case_status":23,"posted_date":45,"marcs_cms_no":46,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":47,"body_fetched_at":48,"delivery_method":49,"recipient_title":19,"reference_number":50,"action_taken_date":51,"medical_device_id":19,"response_letter_date":19},1000,[35,36,37,11,12,13,13,13],"\u003Ctime datetime=\"2025-03-18T04:00:00Z\">03\u002F18\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-03-10T04:00:00Z\">03\u002F10\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finternational-laboratories-corp-698522-03102025\">International Laboratories Corp\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-52\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Robert C. Munday\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Quality and Regulatory Advisor\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>International Laboratories Corp\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Bangplee District, 62 Moo 8,\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bang Na-Trat Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bang Phli\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Samut Prakan\u003C\u002Fspan> \u003Cspan>10540\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Thailand\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-52\u003C\u002Fp>\u003Cp>March 10, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Munday:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, International Laboratories Corp, FEI 3006403166, at Bangplee District, 62 Moo 8, Bang Na-Trat Rd, Bang Phli, Samut Prakan 10540, Thailand, from September 16 to 20, 2024.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your October 11, 2024 response to our Form FDA 483 in detail.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your laboratory records lacked complete and reliable original data to support the chromatographic analyses performed on over-the-counter (OTC) drug products and components. For example, our investigators documented multiple examples of fabricated laboratory records. During the inspection, your Laboratory Manager stated that your firm fabricated several laboratory investigations that were not performed. A senior Quality Assurance Manger also confirmed that laboratory investigations were fabricated in preparation for the FDA inspection. Further, you did not maintain the original data from the analytical testing of raw materials and finished products.\u003C\u002Fp>\u003Cp>In your response, you acknowledge that your laboratory system lacks appropriate procedures and controls to ensure the completeness and integrity of your data and you committed to improvements. Your response is inadequate as it does not adequately evaluate the full scope of data integrity (DI) deficiencies throughout your drug product manufacturing operations.\u003C\u002Fp>\u003Cp>Reliability of data is fundamentally compromised when there is a failure to record or maintain complete and accurate records of test results, or conditions associated with all tests. Furthermore, the lack of reliable data compromises the quality unit’s (QU) ability to exercise its function of ensuring compliance to applicable standards.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your laboratory equipment, used to generate analytical data for finished drug product release and stability testing, lacked restricted access and sufficient controls. Specifically, your firm did not have proper controls in place to prevent the deletion or record manipulation of your laboratory's electronic raw data. For example, our investigator documented numerous examples of deleted electronic raw data files. Additionally, your analysts had administrative rights capable of altering and deleting data, files, and folders on your chromatographic systems, including the date and time of tests.\u003C\u002Fp>\u003Cp>We also note that you did not ensure retention of complete electronic raw data for all laboratory instrumentation and equipment. For example, our investigators documented several electronic data results that were not available for review.\u003C\u002Fp>\u003Cp>In your response, you acknowledge the lack of document control and state that you have initiated change controls to reduce DI gaps identified during the inspection. Your response is inadequate because you failed to include a comprehensive review of each piece of equipment and the impact of the significant adverse pattern of data that has been discarded or lost. Your impact assessment commitment is also limited to missing \u003Cstrong>(b)(4)\u003C\u002Fstrong> test data and stability.\u003C\u002Fp>\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance With\u003C\u002Fem> \u003Cem>Drug CGMP\u003C\u002Fem> for guidance on establishing and following CGMP compliant DI practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\u003Cp>We strongly recommend that you retain an independent third-party qualified consultant to assist in your remediation. In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\u003Cbr>o A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\u003Cbr>o Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\u003Cbr>o An assessment of the extent of DI deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered DI lapses. o A comprehensive retrospective evaluation of the nature of the testing\u002Fmanufacturing\u002Fother DI deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all DI lapses.\u003C\u002Fli>\u003Cli>A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of DI and analyses of the risks posed by ongoing operations.\u003C\u002Fli>\u003Cli>A management strategy for your firm that includes the details of your global corrective action and preventive action (CAPA) plan. Your strategy should include:\u003Cbr>o A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate, including analytical data, manufacturing records, and all data submitted to FDA.\u003Cbr>o A comprehensive description of the root causes of your DI lapses, including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for DI lapses remain able to influence CGMP-related or drug application data at your firm.\u003Cbr>o Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\u003Cbr>o Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\u003Cbr>o A commitment to have a qualified consultant conduct extensive annual audits, for at least 2 years, to assist in evaluating CAPA effectiveness after you have executed your DI remediation protocol.\u003Cbr>o Inform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to receive anonymous complaints from employees reporting DI concerns and with the authority to ensure any potential breach is promptly investigated (by independent quality assurance function, along with expertise from outside entities whenever needed).\u003Cbr>o A status report for any of the above activities already underway or completed.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your QU did not provide adequate oversight for the manufacture of your products. For example, you stated that you could not provide records to support the CGMP requirements for the manufacture of drugs, including but not limited to the following:\u003C\u002Fp>\u003Cul>\u003Cli>Finished product original release testing data\u003C\u002Fli>\u003Cli>Original stability testing data\u003C\u002Fli>\u003Cli>Sample collection and preparation\u003C\u002Fli>\u003Cli>Procedures for quality control data review (e.g., raw material, finished product release, and stability testing)\u003C\u002Fli>\u003Cli>Batch production and control record\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you state that controls are being implemented to establish requirements for CGMP activities across operations and laboratory staff. Your response is inadequate. You failed to address the potential impacts on all drug product lots distributed to the United States that remain within expiry and were manufactured without documentation of testing performed.\u003C\u002Fp>\u003Cp>In a previous warning letter (320-23-34), FDA cited similar CGMP violations. You proposed remediation and committed to conducting a full six-system audit with a qualified CGMP consultant in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\u003Cp>See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>In your response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003Cbr>o Also describe how top management supports quality assurance and reliable operations, including but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>FDA placed your firm on Import Alert 66-40 on August 7, 2023, after your response to our 704(a)(4) Request for Records sent to you on March 17, 2023, demonstrated CGMP violations related to controls for DEG\u002FEG in high-risk components used in your drugs.\u003C\u002Fp>\u003Cp>The inspectional findings detailed above further demonstrate your firm’s noncompliance.\u003C\u002Fp>\u003Cp>Your firm remains on Import Alert 66-40.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at International Laboratories Corp, Bang Phli, Samut Prakan 10540, Thailand, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3006403166 and ATTN: Zachary Bogorad.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-25-52\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Robert C. Munday\n\nRecipient Title\n\nQuality and Regulatory Advisor\n\nInternational Laboratories Corp\n\nBangplee District, 62 Moo 8,\n\nBang Na-Trat Rd\n\nBang Phli\n\nSamut Prakan 10540\n\nThailand\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-52\nMarch 10, 2025\nDear Mr. Munday:\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, International Laboratories Corp, FEI 3006403166, at Bangplee District, 62 Moo 8, Bang Na-Trat Rd, Bang Phli, Samut Prakan 10540, Thailand, from September 16 to 20, 2024.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your October 11, 2024 response to our Form FDA 483 in detail.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).\nYour laboratory records lacked complete and reliable original data to support the chromatographic analyses performed on over-the-counter (OTC) drug products and components. For example, our investigators documented multiple examples of fabricated laboratory records. During the inspection, your Laboratory Manager stated that your firm fabricated several laboratory investigations that were not performed. A senior Quality Assurance Manger also confirmed that laboratory investigations were fabricated in preparation for the FDA inspection. Further, you did not maintain the original data from the analytical testing of raw materials and finished products.\nIn your response, you acknowledge that your laboratory system lacks appropriate procedures and controls to ensure the completeness and integrity of your data and you committed to improvements. Your response is inadequate as it does not adequately evaluate the full scope of data integrity (DI) deficiencies throughout your drug product manufacturing operations.\nReliability of data is fundamentally compromised when there is a failure to record or maintain complete and accurate records of test results, or conditions associated with all tests. Furthermore, the lack of reliable data compromises the quality unit’s (QU) ability to exercise its function of ensuring compliance to applicable standards.\n2. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).\nYour laboratory equipment, used to generate analytical data for finished drug product release and stability testing, lacked restricted access and sufficient controls. Specifically, your firm did not have proper controls in place to prevent the deletion or record manipulation of your laboratory's electronic raw data. For example, our investigator documented numerous examples of deleted electronic raw data files. Additionally, your analysts had administrative rights capable of altering and deleting data, files, and folders on your chromatographic systems, including the date and time of tests.\nWe also note that you did not ensure retention of complete electronic raw data for all laboratory instrumentation and equipment. For example, our investigators documented several electronic data results that were not available for review.\nIn your response, you acknowledge the lack of document control and state that you have initiated change controls to reduce DI gaps identified during the inspection. Your response is inadequate because you failed to include a comprehensive review of each piece of equipment and the impact of the significant adverse pattern of data that has been discarded or lost. Your impact assessment commitment is also limited to missing (b)(4) test data and stability.\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant DI practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\nWe strongly recommend that you retain an independent third-party qualified consultant to assist in your remediation. In response to this letter, provide:\nA comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\no A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\no Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\no An assessment of the extent of DI deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered DI lapses. o A comprehensive retrospective evaluation of the nature of the testing\u002Fmanufacturing\u002Fother DI deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all DI lapses.\nA current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of DI and analyses of the risks posed by ongoing operations.\nA management strategy for your firm that includes the details of your global corrective action and preventive action (CAPA) plan. Your strategy should include:\no A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate, including analytical data, manufacturing records, and all data submitted to FDA.\no A comprehensive description of the root causes of your DI lapses, including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for DI lapses remain able to influence CGMP-related or drug application data at your firm.\no Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\no Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\no A commitment to have a qualified consultant conduct extensive annual audits, for at least 2 years, to assist in evaluating CAPA effectiveness after you have executed your DI remediation protocol.\no Inform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to receive anonymous complaints from employees reporting DI concerns and with the authority to ensure any potential breach is promptly investigated (by independent quality assurance function, along with expertise from outside entities whenever needed).\no A status report for any of the above activities already underway or completed.\n3. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\nYour QU did not provide adequate oversight for the manufacture of your products. For example, you stated that you could not provide records to support the CGMP requirements for the manufacture of drugs, including but not limited to the following:\nFinished product original release testing data\nOriginal stability testing data\nSample collection and preparation\nProcedures for quality control data review (e.g., raw material, finished product release, and stability testing)\nBatch production and control record\nIn your response, you state that controls are being implemented to establish requirements for CGMP activities across operations and laboratory staff. Your response is inadequate. You failed to address the potential impacts on all drug product lots distributed to the United States that remain within expiry and were manufactured without documentation of testing performed.\nIn a previous warning letter (320-23-34), FDA cited similar CGMP violations. You proposed remediation and committed to conducting a full six-system audit with a qualified CGMP consultant in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\nSee FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nIn your response to this letter, provide:\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU disposition decision.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\no Also describe how top management supports quality assurance and reliable operations, including but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nFDA placed your firm on Import Alert 66-40 on August 7, 2023, after your response to our 704(a)(4) Request for Records sent to you on March 17, 2023, demonstrated CGMP violations related to controls for DEG\u002FEG in high-risk components used in your drugs.\nThe inspectional findings detailed above further demonstrate your firm’s noncompliance.\nYour firm remains on Import Alert 66-40.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at International Laboratories Corp, Bang Phli, Samut Prakan 10540, Thailand, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3006403166 and ATTN: Zachary Bogorad.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","International Laboratories Corp","international-laboratories-corp-698522-03102025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finternational-laboratories-corp-698522-03102025","2026-10-26T08:08:59.92861+00:00","2025-03-18","698522","Mr. Robert C. Munday","2026-08-19T16:56:13.206+00:00","VIA UPS","320-25-52","2025-03-10",{"id":53,"raw":54,"subject":59,"body_html":60,"body_text":61,"firm_name":62,"letter_id":63,"created_at":64,"fei_number":19,"letter_url":65,"updated_at":66,"action_type":22,"case_status":23,"posted_date":67,"marcs_cms_no":68,"product_type":26,"closeout_date":19,"issuing_office":58,"recipient_name":69,"body_fetched_at":70,"delivery_method":49,"recipient_title":19,"reference_number":19,"action_taken_date":71,"medical_device_id":19,"response_letter_date":19},1920,[55,56,57,58,59,13,13,13],"\u003Ctime datetime=\"2023-08-22T13:20:00Z\">08\u002F22\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-08-08T04:00:00Z\">08\u002F08\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finternational-laboratories-corp-ltd-664352-08082023\">International Laboratories Corp. Ltd.\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Arniruj Shinaprapha\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Technical Compliance Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>International Laboratories Corp. Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>62 Moo 8, Bangna-Trad Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bang Phli\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>10540\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Thailand\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ra@ilc-cosmetic.com\"> ra@ilc-cosmetic.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:apr@ilc-cosmetic.com\"> apr@ilc-cosmetic.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-23-34\u003C\u002Fp>\n\n\u003Cp>August 8, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Arniruj Shinaprapha:\u003C\u002Fp>\n\n\u003Cp>Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our March 17, 2023 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, International Laboratories Corp. Ltd., FEI 3006403166, 62 Moo 8, Bangna-Trad Road, Bang Phli, Thailand.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\n\n\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant violations were observed, including, but not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You manufacture OTC drug products including \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Based on the records and information you provided, you did not demonstrate that you adequately tested each shipment of each lot of the incoming components at high-risk of \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination. These include, but are not limited to, testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> you used in manufacturing drug products to determine their appropriate identity. Identity testing for these and certain other high-risk drug components\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> includes a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A commitment to provide \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\n\t\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination. Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong>, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective action and preventive action (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificate of analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\u003C\u002Fli>\n\t\u003Cli>The chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\t\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\n\t\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The records and information you provided demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. Specifically, your QU did not adequately exercise its authority in the approval or rejection of components in your Materials System.\u003C\u002Fp>\n\n\u003Cp>Your QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may also not be conducting appropriate oversight regarding other CGMP operations, including Production, Facilities &amp; Equipment, Laboratory Controls, and Packaging &amp; Labelling Systems.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations \u003C\u002Fem>for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on August 7, 2023.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect your facility to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 30 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with 3006403166 and ATTN: Kevin Maguire.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>CC: U.S. Agent:\u003Cbr>\nMr. Manoj Zacharias\u003Cbr>\nLiberty Management Group, Ltd.\u003Cbr>\n75 Executive Drive\u003Cbr>\nSuite 114\u003Cbr>\nAurora, IL 60504\u003Cbr>\nmanoj@libertymanagement.us\u003Cbr>\noffice@libertymanagement.us\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Components with higher risk of \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination compared to other drug components.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> i.e., Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nArniruj Shinaprapha\n\nRecipient Title\n\nTechnical Compliance Officer\n\nInternational Laboratories Corp. Ltd.\n\n62 Moo 8, Bangna-Trad Road\n\nBang Phli\n\n10540\n\nThailand\n\nra@ilc-cosmetic.com\n\napr@ilc-cosmetic.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-23-34\n\nAugust 8, 2023\n\nDear Arniruj Shinaprapha:\n\nYour facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our March 17, 2023 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, International Laboratories Corp. Ltd., FEI 3006403166, 62 Moo 8, Bangna-Trad Road, Bang Phli, Thailand.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B)).\n\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed, including, but not limited to, the following:\n\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\n\nYou manufacture OTC drug products including (b)(4). Based on the records and information you provided, you did not demonstrate that you adequately tested each shipment of each lot of the incoming components at high-risk of (b)(4) or (b)(4) contamination. These include, but are not limited to, testing of (b)(4) and (b)(4) you used in manufacturing drug products to determine their appropriate identity. Identity testing for these and certain other high-risk drug components1 includes a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of (b)(4) or (b)(4). Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in manufacture of your drug products.\n\n(b)(4)\n\nIn response to this letter, provide:\n\nA commitment to provide (b)(4) and (b)(4) test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of (b)(4) and (b)(4).\n\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for (b)(4) or (b)(4) contamination. Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain (b)(4) or (b)(4), including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective action and preventive action (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificate of analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of (b)(4), (b)(4), and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\n\nThe chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\n\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\n\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\n\n2. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\n\nThe records and information you provided demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. Specifically, your QU did not adequately exercise its authority in the approval or rejection of components in your Materials System.\n\nYour QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may also not be conducting appropriate oversight regarding other CGMP operations, including Production, Facilities & Equipment, Laboratory Controls, and Packaging & Labelling Systems.\n\nSee FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide:\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit2 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on August 7, 2023.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect your facility to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 30 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with 3006403166 and ATTN: Kevin Maguire.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCC: U.S. Agent:\n\nMr. Manoj Zacharias\n\nLiberty Management Group, Ltd.\n\n75 Executive Drive\n\nSuite 114\n\nAurora, IL 60504\n\nmanoj@libertymanagement.us\n\noffice@libertymanagement.us\n\n______________________\n\n1 Components with higher risk of (b)(4) or (b)(4) contamination compared to other drug components.\n\n2 i.e., Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","International Laboratories Corp. Ltd.","international-laboratories-corp-ltd-664352-08082023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finternational-laboratories-corp-ltd-664352-08082023","2026-10-26T08:08:59.989411+00:00","2023-08-22","664352","Arniruj Shinaprapha","2026-08-20T00:46:02.487+00:00","2023-08-08",{"id":73,"raw":74,"subject":59,"body_html":79,"body_text":80,"firm_name":81,"letter_id":82,"created_at":83,"fei_number":19,"letter_url":84,"updated_at":85,"action_type":22,"case_status":23,"posted_date":86,"marcs_cms_no":87,"product_type":26,"closeout_date":19,"issuing_office":78,"recipient_name":88,"body_fetched_at":89,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":90,"medical_device_id":19,"response_letter_date":19},2716,[75,76,77,78,59,13,13,13],"\u003Ctime datetime=\"2022-04-26T13:20:00Z\">04\u002F26\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-03-01T05:00:00Z\">03\u002F01\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fclinical-resolution-laboratory-inc-615236-03012022\">Clinical Resolution Laboratory Inc.\u003C\u002Fa>","Division of Pharmaceutical Quality Operations IV","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Justin S. Lee\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Clinical Resolution Laboratory Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1400 W. Lambert Rd., Ste. C\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Brea\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92821-2874\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:justin@clinicalresolution.com\"> justin@clinicalresolution.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations IV\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>March 1, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Lee:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration inspected your drug manufacturing facility, Clinical Resolution Laboratory Inc., FEI 3005727243 at 1400 W. Lambert Rd., Ste. C, Brea, California, from April 6, 2021 to April 27, 2021.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>In addition, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and \"\u003Cstrong>(b)(4)\u003C\u002Fstrong>\"\u003Cstrong>&nbsp;\u003C\u002Fstrong>are unapproved new drugs in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C 355(a), and are also misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>We reviewed your May 18, 2021 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\u003Cbr>\n\u003Cbr>\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to provide data to demonstrate that the manufacturing processes for your OTC drug products have been validated. During the inspection, you were unable to provide documentation to support manufacturing conditions for each of the OTC drug products. There were no qualification protocols, reports, or studies to demonstrate that each drug product met predetermined quality requirements consistently and reliably. Furthermore, you did not have an ongoing program for monitoring process control to ensure stable manufacturing operations and consistent drug quality.\u003C\u002Fp>\n\n\u003Cp>In your response, you acknowledged the validation studies for manufacturing processes had not been documented and that you would perform retrospective validations by evaluating the last \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You failed to provide a detailed process performance protocol for your validations or actions to be implemented to identify all sources of variability. Furthermore, your response did not provide a timeline for completion of prospective PPQ studies for each of your drug products. The use of a retrospective validation approach is not acceptable. Lastly, you did not address the impact this violation has on your drug products currently in the market.\u003C\u002Fp>\n\n\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established.\u003C\u002Fp>\n\n\u003Cp>Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>In response, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process design, process performance qualification, and vigilant ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003Cbr>\n• A timeline for performing appropriate process performance qualification (PPQ) for each of your marketed drug products.\u003Cbr>\n• Include your process performance protocols, and written procedures for qualification of equipment and facilities.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>2. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You did not validate the cleaning processes used for cleaning non-dedicated manufacturing equipment, such as Mixing Tank \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which is used for your human drug and cosmetic products. Additionally, your practice of evaluating cleaning effectiveness for microbiological contamination via \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong> was not validated.\u003C\u002Fp>\n\n\u003Cp>Inadequate removal of microbiological and product residues from surfaces of non-dedicated manufacturing equipment can lead to contamination of drug products subsequently manufactured on that equipment.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that you will write and execute a validation protocol to evaluate your cleaning procedures. Additionally, you plan to validate the \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You did not provide a comprehensive assessment of your cleaning processes for all equipment as well as your cleaning validation protocol and report. Additionally, you did not provide interim measures to assure non-dedicated manufacturing equipment is appropriately cleaned until cleaning validation studies are complete.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide\u003Cbr>\n• Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\u003Cbr>\n&nbsp; o drugs with higher toxicities\u003Cbr>\n&nbsp; o drugs with higher drug potencies\u003Cbr>\n&nbsp; o drugs of lower solubility in their cleaning solvents\u003Cbr>\n&nbsp; o drugs with characteristics that make them difficult to clean\u003Cbr>\n&nbsp; o swabbing locations for areas that are most difficult to clean\u003Cbr>\n&nbsp; o maximum hold times before cleaning\u003Cbr>\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003Cbr>\n• A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003Cbr>\n• A CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You released your OTC topical drug products prior to completing and reviewing all quality control testing. Specifically, your \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Lot No. \u003Cstrong>(b)(4)\u003C\u002Fstrong> was released by your quality unit on July 2, 2020. However, final contract laboratory testing for active assay and microbiological quality was not reported to your firm until July 20, 2020 and July 22, 2020, respectively.\u003C\u002Fp>\n\n\u003Cp>Testing, prior to batch disposition, is essential to ensure that the drug products you manufacture conform to all pre-determined quality attributes that are appropriate for their intended use, including both chemical and microbiological specifications.\u003C\u002Fp>\n\n\u003Cp>In your response, it was stated the root cause of releasing drug product prior to completion of all quality control testing was “due to the belief that such could be proceeded to next step with customer’s approval.” Additionally, you modified your standard operating procedure regarding the process for releasing drug product.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You did not perform a retrospective review of all drug product batches within expiry to identify other instances in which drug product was released by the quality unit prior to completion of quality control testing. Notably, this was a repeat observation from your May 8 to May 15, 2018 FDA inspection.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed corrective action and preventive action plan (CAPA) and provisions for evaluating its effectiveness.\u003Cbr>\n• An updated list of chemical and microbiological specifications, including test methods, used to analyze each batch of your drug products prior to a batch disposition decision.\u003Cbr>\n• The actions you will take to determine the overall quality of your U.S. drug product batches within expiry which were previously released prior to adequate QU review. Specifically, determine whether an effective and complete final review of each batch and its related information was conducted before the QU disposition decision. In addition, provide an independent third-party assessment of your current system for batch disposition in a CAPA to remediate all deficiencies.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm lacked an adequate quality unit (QU). For example, your quality unit failed to establish procedures describing QU roles, responsibilities, and authorities. Furthermore, your QU’s oversight of your drug manufacturing operations was inadequate. For example, your QU failed to perform the following:\u003C\u002Fp>\n\n\u003Cp>• Provide adequate CGMP training to personnel.\u003Cbr>\n• Evaluate and investigate discrepancies and out-of-specification results.\u003Cbr>\n• Maintain and investigate customer complaints.\u003Cbr>\n• Establish and maintain adequate procedures with your contract testing laboratories, for example a quality agreement.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that you have faced difficulties in recruiting qualified personnel for QU functions during the COVID-19 pandemic.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Many of the failures of the QU were observed during the previous inspection, dated May 8 to May 15, 2018. Many of your commitments from that inspection were not implemented.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide a comprehensive independent assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fp>\n\n\u003Cp>• A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>\n• Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>\n• Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fp>\n\n\u003Cp>Also, describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002F quality issues and to assure a continuing state of control.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Use of Contract Manufacturers\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Drugs must be manufactured in conformance with CGMP. The FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. The FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\n\n\u003Cp>You are responsible for the quality of your drugs, regardless of agreements in place with your CMOs. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act to ensure safety, identity, strength, quality, and purity. See the FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002Fdrugs\u002Fguidances\u002Fucm353925.pdf\">https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002Fdrugs\u002Fguidances\u002Fucm353925.pdf\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. See the FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Repeat Observations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In a previous inspection, dated May 8 to May 15, 2018, the FDA cited similar CGMP observations. You proposed specific remediations for these observations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Because you failed to correct repeat violations, we strongly recommend engaging a consultant as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21, U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, these products are intended for use as skin bleaching products; topical anorectal products; topical external analgesic products; and topical antifungal drug products, respectively.\u003C\u002Fp>\n\n\u003Cp>Examples of claims from the products’ labeling, including websites listed on product labels, that provide evidence of the intended uses (as defined by 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We note that, as of the date of this letter, some of the claims cited above appear to have been removed. Due to the public health concerns related to the marketing and sale of unapproved drugs for the intended uses described above, it is essential that these violations do not recur.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Skin Bleaching Products\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Based on the above labeling claims, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” are intended for use as skin bleaching drug products. As described below, these skin bleaching drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> are skin bleaching drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these skin bleaching products fall under section 505G(a)(4) of the FD&amp;C Act, 21 U.S.C. 355h(a)(4), because they are subject to a determination to be not generally recognized as safe and effective (GRASE) in a proposed rule that is the most recently applicable proposal issued under 21 CFR part 330.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Thus, \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> are deemed to be new drugs under section 201(p)(1) of the FD&amp;C Act and subject to the requirement to have an approved new drug application under section 505 of the FD&amp;C Act, 21 U.S.C. 355, beginning on September 23, 2020.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products. Accordingly, these skin bleaching drug products are unapproved new drugs marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Topical Anorectal Drug Products\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Based on the above labeling claims, \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> are topical products intended for use as anorectal drugs, among other uses. As described below, these topical anorectal drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>In general, a drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not GRASE for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for the three products identified above.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> are topical anorectal drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. In particular, topical anorectal drug products are deemed to be GRASE and not a “new drug” if, among other things, they conform to the conditions of use set forth in the Over-the-Counter Monograph MO15: Anorectal Drug Products for Over-the-Counter Human Use (hereinafter “M015”).\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> However, these topical anorectal drug products do not conform to the conditions of use specified in Monograph M015 because the products include indications not covered under M015, such as use as a numbing cream for clinical procedures (\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and use on anal fissures (\u003Cstrong>(b)(4)\u003C\u002Fstrong>). Therefore, these products do not meet requirements under section 505G, under which they would be deemed to be GRASE and not a new drug.\u003C\u002Fp>\n\n\u003Cp>In addition, the FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “Ebanel NUMB 520 Topical Anesthetic Cream,” “NUMB MASTER Topical Anesthetic Cream,” or “Ebanel HEMORRHOID MASTER HEMORRHOID &amp; FISSURE OINTMENT” are GRASE for use under the conditions prescribed, recommended or suggested in their labeling. Moreover, there is no evident basis under the FD&amp;C Act under which these products would be legally marketed without an approved application. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) of the FD&amp;C Act. Introduction or delivery for introduction of such products into interstate commerce is prohibited under section and 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>External Analgesic Drug Product\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Based on the above labeling claims, \u003Cstrong>(b)(4)\u003C\u002Fstrong> is a topical product intended for use as an external analgesic, among other uses. As described below, this external analgesic drug product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>As previously noted, in general, a drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not GRASE for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> is an external analgesic drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G of the FD&amp;C Act, certain nonprescription drugs without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. In particular, topical products intended for use as an external analgesic are deemed to be GRASE and not a “new drug” if, among other things, they conform to the tentative final monograph (TFM) that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330. We note that OTC topical external analgesic products were addressed in the TFM for External Analgesic Drug Products for Over-the-Counter Human Use (external analgesic TFM; 48 FR 5852, February 8, 1983) and subsequent rulemakings. The 1983 external analgesic TFM, in combination with subsequent determinations, was deemed to be a final administrative order.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> However,&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> product does not conform to the conditions of use specified in the final administrative order, because the product’s active ingredients, \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, are not active ingredients in any applicable final monograph or TFM. Although the product labeling does not specifically list these ingredients as active ingredients, the claims for these specific ingredients, as noted above, demonstrate that these are each an “active ingredient” as defined in 21 CFR 201.66(b)(2) because each ingredient is intended to furnish pharmacological activity.\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Thus, \u003Cstrong>(b)(4)\u003C\u002Fstrong> product does not meet requirements under section 505G of the FD&amp;C Act, under which it would be deemed to be GRASE and not a new drug.\u003C\u002Fp>\n\n\u003Cp>In addition, the FDA is not aware of any adequate and well-controlled clinical studies in the published literature that support a determination that \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling. Moreover, there is no evident basis under the FD&amp;C Act under which this product would be legally marketed without an approved application. Accordingly, this product is an unapproved new drug marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under section and 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Topical Antifungal Product\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Based on the above labeling claims, \u003Cstrong>(b)(4)\u003C\u002Fstrong> is topical product intended for use as an antifungal drug, among other uses. As described below, this topical antifungal drug product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> is an antifungal drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, this antifungal drug falls under section 505G(a)(5) of the FD&amp;C Act, 21 U.S.C. 355h(a)(5), because the FDA has determined that a topical antifungal drug product labeled with claims or directions for use on the scalp or on the nails is not GRASE under a final determination issued under 21 CFR part 330.\u003Csup>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore \u003Cstrong>(b)(4)\u003C\u002Fstrong> is deemed to be a “new drug” within the meaning of section 201(p) of the FD&amp;C Act and is subject to the requirement for an approved new drug application for marketing under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for \u003Cstrong>(b)(4)\u003C\u002Fstrong> topical antifungal drug product. Accordingly, this topical antifungal drug product is an unapproved new drug marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under section and 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Further, \u003Cstrong>(b)(4)\u003C\u002Fstrong> are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, are not the subjects of applications approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355, and do not comply with the requirements under section 505G of the FD&amp;C Act, 21 U.S.C. 355h. Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&amp;C Act, 21 U.S.C. 331(a) and (d).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause the FDA to withhold issuance of Export Certificates. The FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to correct your violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Your response should refer to unique identifier CMS 615236 and be sent electronically to ORAPHARM4_Responses@fda.hhs.gov or mailed to:\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\n19701 Fairchild Road\u003Cbr>\nIrvine, CA 92612\u003C\u002Fp>\n\n\u003Cp>If you have any questions regarding this letter, please contact Jamie Dion, Compliance Officer, at 303-236-3133 or by email at Jamie.Dion@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Lance M. De Souza\u003Cbr>\nActing Director, Division of Pharmaceutical Quality Operations IV\u003C\u002Fp>\n\n\u003Cp>___________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1&nbsp;\u003C\u002Fstrong>\u003C\u002Fem>Drug products intended for skin bleaching, had been the subject of the developing rule for Skin Bleaching Drug Products for OTC Human Use (47 Federal Register (FR) 39108, September 3, 1982). On August 29, 2006, FDA issued a proposed rule (71 FR 51146) setting forth a determination that OTC skin bleaching drug products, including but not limited to those that contain hydroquinone, are not generally recognized as safe and effective.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> FDA did not determine that it was in the interest of public health to extend the period during which any drugs subject to section 505G(a)(4) may be marketed without an approved new drug application.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Section 505G(a)(1) of the FD&amp;C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs\", notably conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 C.F.R. part 330, prior to enactment of the CARES Act. In the case of OTC topical anorectal drug products, relevant documents were deemed under section 505G to be a final administrative order, Over-the-Counter Monograph M015: Anorectal Drug Products for Over-the-Counter Human Use. (See Order ID OTC000009, available at FDA’s website OTC Monographs@FDA, \u003Ca href=\"https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002Findex.cfmURL\">https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002Findex.cfmURL\u003C\u002Fa>.)\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Section 505G(a)(1) of the FD&amp;C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs\", notably conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 C.F.R. part 330, prior to enactment of the CARES Act. In the case of OTC topical external analgesic products, relevant documents were deemed under section 505G to be a final administrative order.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5&nbsp;\u003C\u002Fstrong>\u003C\u002Fem>Under 21 CFR 201.66(b), an active ingredient is a component of a drug intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> On September 2, 1993, FDA issued a final rule establishing that certain labeling claims for OTC topical antifungal drug products, including for use on scalp or on the nails, are not generally recognized as safe and effective. 58 Fed. Reg. 46744. FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(22)(iii). Under section 505G(k)(2)(A) of the FD&amp;C Act, the non-monograph conditions in 21 CFR 310.545 in effect on the day before the date of enactment of the CARES Act (i.e., March 26, 2020) were deemed to be a final administrative order. The final administrative order is entitled “Non-Monograph Conditions NM900: Drug Products Containing Certain Active Ingredients Offered Over-the-Counter for Certain Uses” (See Order ID OTC 000007, available at OTC Monographs@FDA, \u003Ca href=\"https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002Findex.cfmURL\">https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002Findex.cfmURL\u003C\u002Fa>.)\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Justin S. Lee\n\nRecipient Title\n\nPresident\n\nClinical Resolution Laboratory Inc.\n\n1400 W. Lambert Rd., Ste. C\n\nBrea, CA 92821-2874\n\nUnited States\n\njustin@clinicalresolution.com\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations IV\n\nUnited States\n\nWARNING LETTER\n\nMarch 1, 2022\n\nDear Mr. Lee:\n\nThe U.S. Food and Drug Administration inspected your drug manufacturing facility, Clinical Resolution Laboratory Inc., FEI 3005727243 at 1400 W. Lambert Rd., Ste. C, Brea, California, from April 6, 2021 to April 27, 2021.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nIn addition, “(b)(4)” and \"(b)(4)\" are unapproved new drugs in violation of section 505(a) of the FD&C Act, 21 U.S.C 355(a), and are also misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nWe reviewed your May 18, 2021 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\nYou failed to provide data to demonstrate that the manufacturing processes for your OTC drug products have been validated. During the inspection, you were unable to provide documentation to support manufacturing conditions for each of the OTC drug products. There were no qualification protocols, reports, or studies to demonstrate that each drug product met predetermined quality requirements consistently and reliably. Furthermore, you did not have an ongoing program for monitoring process control to ensure stable manufacturing operations and consistent drug quality.\n\nIn your response, you acknowledged the validation studies for manufacturing processes had not been documented and that you would perform retrospective validations by evaluating the last (b)(4) batches.\n\nYour response is inadequate. You failed to provide a detailed process performance protocol for your validations or actions to be implemented to identify all sources of variability. Furthermore, your response did not provide a timeline for completion of prospective PPQ studies for each of your drug products. The use of a retrospective validation approach is not acceptable. Lastly, you did not address the impact this violation has on your drug products currently in the market.\n\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established.\n\nSuccessful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\n\nIn response, provide the following:\n\n• A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process design, process performance qualification, and vigilant ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\n\n• A timeline for performing appropriate process performance qualification (PPQ) for each of your marketed drug products.\n\n• Include your process performance protocols, and written procedures for qualification of equipment and facilities.\n\n2. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\n\nYou did not validate the cleaning processes used for cleaning non-dedicated manufacturing equipment, such as Mixing Tank (b)(4), which is used for your human drug and cosmetic products. Additionally, your practice of evaluating cleaning effectiveness for microbiological contamination via (b)(4) testing for (b)(4) was not validated.\n\nInadequate removal of microbiological and product residues from surfaces of non-dedicated manufacturing equipment can lead to contamination of drug products subsequently manufactured on that equipment.\n\nIn your response, you stated that you will write and execute a validation protocol to evaluate your cleaning procedures. Additionally, you plan to validate the (b)(4) testing.\n\nYour response is inadequate. You did not provide a comprehensive assessment of your cleaning processes for all equipment as well as your cleaning validation protocol and report. Additionally, you did not provide interim measures to assure non-dedicated manufacturing equipment is appropriately cleaned until cleaning validation studies are complete.\n\nIn response to this letter, provide\n\n• Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\n\no drugs with higher toxicities\n\no drugs with higher drug potencies\n\no drugs of lower solubility in their cleaning solvents\n\no drugs with characteristics that make them difficult to clean\n\no swabbing locations for areas that are most difficult to clean\n\no maximum hold times before cleaning\n\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\n\n• A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n\n• A CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\n\n3. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\n\nYou released your OTC topical drug products prior to completing and reviewing all quality control testing. Specifically, your (b)(4), Lot No. (b)(4) was released by your quality unit on July 2, 2020. However, final contract laboratory testing for active assay and microbiological quality was not reported to your firm until July 20, 2020 and July 22, 2020, respectively.\n\nTesting, prior to batch disposition, is essential to ensure that the drug products you manufacture conform to all pre-determined quality attributes that are appropriate for their intended use, including both chemical and microbiological specifications.\n\nIn your response, it was stated the root cause of releasing drug product prior to completion of all quality control testing was “due to the belief that such could be proceeded to next step with customer’s approval.” Additionally, you modified your standard operating procedure regarding the process for releasing drug product.\n\nYour response is inadequate. You did not perform a retrospective review of all drug product batches within expiry to identify other instances in which drug product was released by the quality unit prior to completion of quality control testing. Notably, this was a repeat observation from your May 8 to May 15, 2018 FDA inspection.\n\nIn response to this letter, provide:\n\n• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed corrective action and preventive action plan (CAPA) and provisions for evaluating its effectiveness.\n\n• An updated list of chemical and microbiological specifications, including test methods, used to analyze each batch of your drug products prior to a batch disposition decision.\n\n• The actions you will take to determine the overall quality of your U.S. drug product batches within expiry which were previously released prior to adequate QU review. Specifically, determine whether an effective and complete final review of each batch and its related information was conducted before the QU disposition decision. In addition, provide an independent third-party assessment of your current system for batch disposition in a CAPA to remediate all deficiencies.\n\n4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour firm lacked an adequate quality unit (QU). For example, your quality unit failed to establish procedures describing QU roles, responsibilities, and authorities. Furthermore, your QU’s oversight of your drug manufacturing operations was inadequate. For example, your QU failed to perform the following:\n\n• Provide adequate CGMP training to personnel.\n\n• Evaluate and investigate discrepancies and out-of-specification results.\n\n• Maintain and investigate customer complaints.\n\n• Establish and maintain adequate procedures with your contract testing laboratories, for example a quality agreement.\n\nIn your response, you stated that you have faced difficulties in recruiting qualified personnel for QU functions during the COVID-19 pandemic.\n\nYour response is inadequate. Many of the failures of the QU were observed during the previous inspection, dated May 8 to May 15, 2018. Many of your commitments from that inspection were not implemented.\n\nIn response to this letter, provide a comprehensive independent assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\n• A determination of whether procedures used by your firm are robust and appropriate.\n\n• Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\n• Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n\nAlso, describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002F quality issues and to assure a continuing state of control.\n\nUse of Contract Manufacturers\n\nDrugs must be manufactured in conformance with CGMP. The FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. The FDA regards contractors as extensions of the manufacturer.\n\nYou are responsible for the quality of your drugs, regardless of agreements in place with your CMOs. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act to ensure safety, identity, strength, quality, and purity. See the FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002Fdrugs\u002Fguidances\u002Fucm353925.pdf.\n\nQuality Systems\n\nYour firm’s quality systems are inadequate. See the FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nRepeat Observations at Facility\n\nIn a previous inspection, dated May 8 to May 15, 2018, the FDA cited similar CGMP observations. You proposed specific remediations for these observations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\n\nConsultant Recommended\n\nBecause you failed to correct repeat violations, we strongly recommend engaging a consultant as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nUnapproved New Drug Violations\n\n(b)(4) are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21, U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, these products are intended for use as skin bleaching products; topical anorectal products; topical external analgesic products; and topical antifungal drug products, respectively.\n\nExamples of claims from the products’ labeling, including websites listed on product labels, that provide evidence of the intended uses (as defined by 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\n\n(b)(4)\n\nWe note that, as of the date of this letter, some of the claims cited above appear to have been removed. Due to the public health concerns related to the marketing and sale of unapproved drugs for the intended uses described above, it is essential that these violations do not recur.\n\nSkin Bleaching Products\n\nBased on the above labeling claims, “(b)(4)” are intended for use as skin bleaching drug products. As described below, these skin bleaching drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\n(b)(4) are skin bleaching drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these skin bleaching products fall under section 505G(a)(4) of the FD&C Act, 21 U.S.C. 355h(a)(4), because they are subject to a determination to be not generally recognized as safe and effective (GRASE) in a proposed rule that is the most recently applicable proposal issued under 21 CFR part 330.1 Thus, (b)(4) and (b)(4) are deemed to be new drugs under section 201(p)(1) of the FD&C Act and subject to the requirement to have an approved new drug application under section 505 of the FD&C Act, 21 U.S.C. 355, beginning on September 23, 2020.2\n\nNo FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for (b)(4) or (b)(4) drug products. Accordingly, these skin bleaching drug products are unapproved new drugs marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\n\nTopical Anorectal Drug Products\n\nBased on the above labeling claims, (b)(4) and (b)(4) are topical products intended for use as anorectal drugs, among other uses. As described below, these topical anorectal drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nIn general, a drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not GRASE for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for the three products identified above.\n\n(b)(4) and (b)(4) are topical anorectal drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. In particular, topical anorectal drug products are deemed to be GRASE and not a “new drug” if, among other things, they conform to the conditions of use set forth in the Over-the-Counter Monograph MO15: Anorectal Drug Products for Over-the-Counter Human Use (hereinafter “M015”).3 However, these topical anorectal drug products do not conform to the conditions of use specified in Monograph M015 because the products include indications not covered under M015, such as use as a numbing cream for clinical procedures ((b)(4) and (b)(4)) and use on anal fissures ((b)(4)). Therefore, these products do not meet requirements under section 505G, under which they would be deemed to be GRASE and not a new drug.\n\nIn addition, the FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “Ebanel NUMB 520 Topical Anesthetic Cream,” “NUMB MASTER Topical Anesthetic Cream,” or “Ebanel HEMORRHOID MASTER HEMORRHOID & FISSURE OINTMENT” are GRASE for use under the conditions prescribed, recommended or suggested in their labeling. Moreover, there is no evident basis under the FD&C Act under which these products would be legally marketed without an approved application. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) of the FD&C Act. Introduction or delivery for introduction of such products into interstate commerce is prohibited under section and 301(d) of the FD&C Act, 21 U.S.C. 331(d).\n\nExternal Analgesic Drug Product\n\nBased on the above labeling claims, (b)(4) is a topical product intended for use as an external analgesic, among other uses. As described below, this external analgesic drug product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nAs previously noted, in general, a drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not GRASE for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for the (b)(4) drug product.\n\n(b)(4) is an external analgesic drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G of the FD&C Act, certain nonprescription drugs without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. In particular, topical products intended for use as an external analgesic are deemed to be GRASE and not a “new drug” if, among other things, they conform to the tentative final monograph (TFM) that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330. We note that OTC topical external analgesic products were addressed in the TFM for External Analgesic Drug Products for Over-the-Counter Human Use (external analgesic TFM; 48 FR 5852, February 8, 1983) and subsequent rulemakings. The 1983 external analgesic TFM, in combination with subsequent determinations, was deemed to be a final administrative order.4 However, (b)(4) product does not conform to the conditions of use specified in the final administrative order, because the product’s active ingredients, (b)(4) and (b)(4), are not active ingredients in any applicable final monograph or TFM. Although the product labeling does not specifically list these ingredients as active ingredients, the claims for these specific ingredients, as noted above, demonstrate that these are each an “active ingredient” as defined in 21 CFR 201.66(b)(2) because each ingredient is intended to furnish pharmacological activity.5 Thus, (b)(4) product does not meet requirements under section 505G of the FD&C Act, under which it would be deemed to be GRASE and not a new drug.\n\nIn addition, the FDA is not aware of any adequate and well-controlled clinical studies in the published literature that support a determination that (b)(4) drug product is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling. Moreover, there is no evident basis under the FD&C Act under which this product would be legally marketed without an approved application. Accordingly, this product is an unapproved new drug marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under section and 301(d) of the FD&C Act, 21 U.S.C. 331(d).\n\nTopical Antifungal Product\n\nBased on the above labeling claims, (b)(4) is topical product intended for use as an antifungal drug, among other uses. As described below, this topical antifungal drug product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\n(b)(4) is an antifungal drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, this antifungal drug falls under section 505G(a)(5) of the FD&C Act, 21 U.S.C. 355h(a)(5), because the FDA has determined that a topical antifungal drug product labeled with claims or directions for use on the scalp or on the nails is not GRASE under a final determination issued under 21 CFR part 330.6 Therefore (b)(4) is deemed to be a “new drug” within the meaning of section 201(p) of the FD&C Act and is subject to the requirement for an approved new drug application for marketing under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nNo FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for (b)(4) topical antifungal drug product. Accordingly, this topical antifungal drug product is an unapproved new drug marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under section and 301(d) of the FD&C Act, 21 U.S.C. 331(d).\n\nMisbranded Drugs\n\nFurther, (b)(4) are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, are not the subjects of applications approved under section 505 of the FD&C Act, 21 U.S.C. 355, and do not comply with the requirements under section 505G of the FD&C Act, 21 U.S.C. 355h. Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. 331(a) and (d).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause the FDA to withhold issuance of Export Certificates. The FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to correct your violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nYour response should refer to unique identifier CMS 615236 and be sent electronically to ORAPHARM4_Responses@fda.hhs.gov or mailed to:\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\nU.S. Food and Drug Administration\n\n19701 Fairchild Road\n\nIrvine, CA 92612\n\nIf you have any questions regarding this letter, please contact Jamie Dion, Compliance Officer, at 303-236-3133 or by email at Jamie.Dion@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nLance M. De Souza\n\nActing Director, Division of Pharmaceutical Quality Operations IV\n\n___________________\n\n1 Drug products intended for skin bleaching, had been the subject of the developing rule for Skin Bleaching Drug Products for OTC Human Use (47 Federal Register (FR) 39108, September 3, 1982). On August 29, 2006, FDA issued a proposed rule (71 FR 51146) setting forth a determination that OTC skin bleaching drug products, including but not limited to those that contain hydroquinone, are not generally recognized as safe and effective.\n\n2 FDA did not determine that it was in the interest of public health to extend the period during which any drugs subject to section 505G(a)(4) may be marketed without an approved new drug application.\n\n3 Section 505G(a)(1) of the FD&C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs\", notably conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 C.F.R. part 330, prior to enactment of the CARES Act. In the case of OTC topical anorectal drug products, relevant documents were deemed under section 505G to be a final administrative order, Over-the-Counter Monograph M015: Anorectal Drug Products for Over-the-Counter Human Use. (See Order ID OTC000009, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002Findex.cfmURL.)\n\n4 Section 505G(a)(1) of the FD&C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs\", notably conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 C.F.R. part 330, prior to enactment of the CARES Act. In the case of OTC topical external analgesic products, relevant documents were deemed under section 505G to be a final administrative order.\n\n5 Under 21 CFR 201.66(b), an active ingredient is a component of a drug intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\n6 On September 2, 1993, FDA issued a final rule establishing that certain labeling claims for OTC topical antifungal drug products, including for use on scalp or on the nails, are not generally recognized as safe and effective. 58 Fed. Reg. 46744. FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(22)(iii). Under section 505G(k)(2)(A) of the FD&C Act, the non-monograph conditions in 21 CFR 310.545 in effect on the day before the date of enactment of the CARES Act (i.e., March 26, 2020) were deemed to be a final administrative order. The final administrative order is entitled “Non-Monograph Conditions NM900: Drug Products Containing Certain Active Ingredients Offered Over-the-Counter for Certain Uses” (See Order ID OTC 000007, available at OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002Findex.cfmURL.)","Clinical Resolution Laboratory Inc.","clinical-resolution-laboratory-inc-615236-03012022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fclinical-resolution-laboratory-inc-615236-03012022","2026-10-26T08:08:15.884222+00:00","2022-04-26","615236","Mr. Justin S. Lee","2026-08-20T01:58:22.559+00:00","2022-03-01",{"id":92,"raw":93,"subject":59,"body_html":99,"body_text":100,"firm_name":101,"letter_id":102,"created_at":64,"fei_number":19,"letter_url":103,"updated_at":104,"action_type":22,"case_status":105,"posted_date":106,"marcs_cms_no":107,"product_type":26,"closeout_date":108,"issuing_office":109,"recipient_name":110,"body_fetched_at":111,"delivery_method":112,"recipient_title":19,"reference_number":19,"action_taken_date":113,"medical_device_id":19,"response_letter_date":19},1584,[94,95,96,97,59,13,98,13],"\u003Ctime datetime=\"2024-03-05T14:20:00Z\">03\u002F05\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-02-15T05:00:00Z\">02\u002F15\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbell-international-laboratories-inc-669736-02152024\">Bell International Laboratories, Inc.\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations III","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbell-international-laboratories-inc-669736-03042026\">\u003Ctime datetime=\"2026-03-12T04:00:00Z\">03\u002F12\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS Next Day\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Mohammed Saremi\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Bell International Laboratories, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2950 Lexington Ave. S., Ste. 100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Eagan\u003C\u002Fspan>, \u003Cspan>MN\u003C\u002Fspan> \u003Cspan>55121\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations III\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>February 15, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCASE# 669736\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Saremi,\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Bell International Laboratories, Inc., FEI 3005574978, at 2950 Lexington Ave. S., Ste. 100, Eagan, from September 11 to 19, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your October 5, 2023 response to our Form FDA 483 in detail.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed (21 CFR 211.22(a) and (d)).\u003C\u002Fstrong>\u003Cbr>\n\u003Cbr>\nYour quality unit (QU) lacked adequate control over your over-the-counter (OTC) drug manufacturing operations and failed to ensure that you had adequate procedures. For example, your QU failed to ensure:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Adequate investigations into non-conformances (21 CFR 211.192).\u003C\u002Fli>\n\t\u003Cli>Adequate investigations into complaints (21 CFR 211.198(a)).\u003C\u002Fli>\n\t\u003Cli>Adequate system for document control and retention (e.g., missing, or incomplete batch records, missing testing records and out-of-specification (OOS) investigations) (21 CFR 211.188).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In your response, you acknowledge that you did not follow your investigation procedures and that many of your investigations were incomplete. You note that you revised your procedures and commit to conducting investigations “as thoroughly as possible.” You also state that the missing production and laboratory records are from 2021 and 2022, and deviations were opened for each occurrence discovered.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because you did not address how you will ensure that investigations contain adequate root cause determinations, corrective action and preventive action (CAPA), and effectiveness checks. You failed to appropriately address the impact of missing records on the quality of the drug products already on the market. You also did not address how you will maintain completeness and accuracy of the records used for batch release and other quality review decisions despite changes or turnover within the QU.\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM070337.pdf.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\n\t\u003Cli>An independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final QU decisions, and is fully supported by executive management.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\n\t\u003Cli>A comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include, but not be limited to, addressing the following:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o QU oversight of laboratory investigations\u003Cbr>\n&nbsp; &nbsp; o Identification of adverse laboratory control trends\u003Cbr>\n&nbsp; &nbsp; o Resolution of causes of laboratory variation\u003Cbr>\n&nbsp; &nbsp; o Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\u003Cbr>\n&nbsp; &nbsp; o Adequate scoping of each investigation and its CAPA\u003Cbr>\n&nbsp; &nbsp; o Revised OOS investigation procedures with these and other remediations\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to perform adequate identity testing on each component lot used to manufacture your OTC drug products. For example, your component identity testing did not include a limit test for diethylene glycol (DEG) and ethylene glycol (EG) on all lots of glycerin before use in the manufacture of your drug products. Identity testing for this and certain other high-risk drug components\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> includes a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform adequate identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene&nbsp;\u003C\u002Fem>\u003Cem>Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In your response, you commit to testing each lot of glycerin for the presence of DEG and EG, and all incoming lots in conformance with the USP monograph for glycerin. You also state that you revised your written procedure for testing of raw materials to include identity testing.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because it lacks specificity regarding your plans to test each lot of each shipment of incoming components. Additionally, you did not consider a retrospective risk assessment for products on the market and within expiry for which you did not conduct adequate identity testing on the components. Without appropriate testing of components, you cannot ensure the quality and safety of your drug products.\u003C\u002Fp>\n\n\u003Cp>FDA cited a similar CGMP observation in a June 2017 inspection.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing reserve samples of all lots of high-risk drug components used in the manufacture of your drug products. Alternatively, if a reserve sample of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\u003C\u002Fli>\n\t\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificate of analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\u003C\u002Fli>\n\t\u003Cli>The chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You did not adequately demonstrate that your manufacturing processes are reproducible and controlled to consistently yield drugs of uniform character and quality. For example, you failed to adequately validate your manufacturing process for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Specifically, for at least two lots, you adjusted the pH during the bulk phase testing using an unvalidated process. During the inspection, you confirmed that this process was not validated.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that for topical drug products, you “default to the established cosmetic regulations because the sample matrices of sunscreens more similarly follow cosmetic formulations.”\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Following requirements for cosmetics does not satisfy the regulations for finished pharmaceuticals. You are responsible for assuring your manufacturing processes will consistently result in drug products meeting predefined quality attributes.\u003C\u002Fp>\n\n\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately to ensure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality are necessary to ensure that you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that FDA considers appropriate elements of process validation, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\n\t\u003Cli>A remediation plan that better assures ongoing management oversight throughout the manufacturing lifecycle of all drug products. Provide a more data-driven and scientifically sound program that identifies sources of process variability, and assures that manufacturing operations meet appropriate parameters and quality standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, ensuring quality of input materials, determining the capability and reliability of each manufacturing process step and its controls, and vigilant ongoing monitoring of process performance and product quality.\u003C\u002Fli>\n\t\u003Cli>Timelines for completing process performance qualification studies on remediated processes for marketed drug products for which a state of control has not been adequately and fully established.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Your reply should refer to case # 669736 and include your FEI 3005574978. Send your electronic reply to ORAPHARM3_RESPONSES@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Attention: Brian Nicholson, Compliance Officer\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nDivision of Pharmaceutical Quality Operations Division III\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, please contact Compliance Officer, Brian Nicholson at (630) 207-9337.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Jeffrey D. Meng\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations Division III\u003C\u002Fp>\n\n\u003Cp>_______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Components with higher risk of DEG or EG contamination compared to other drug components.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> \u003Cem>i.e.\u003C\u002Fem>, Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS Next Day\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Mohammed Saremi\n\nRecipient Title\n\nChief Executive Officer\n\nBell International Laboratories, Inc.\n\n2950 Lexington Ave. S., Ste. 100\n\nEagan, MN 55121\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations III\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nFebruary 15, 2024\n\nWARNING LETTER\n\nCASE# 669736\n\nDear Mr. Saremi,\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Bell International Laboratories, Inc., FEI 3005574978, at 2950 Lexington Ave. S., Ste. 100, Eagan, from September 11 to 19, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your October 5, 2023 response to our Form FDA 483 in detail.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following:\n\n1. Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed (21 CFR 211.22(a) and (d)).\n\nYour quality unit (QU) lacked adequate control over your over-the-counter (OTC) drug manufacturing operations and failed to ensure that you had adequate procedures. For example, your QU failed to ensure:\n\nAdequate investigations into non-conformances (21 CFR 211.192).\n\nAdequate investigations into complaints (21 CFR 211.198(a)).\n\nAdequate system for document control and retention (e.g., missing, or incomplete batch records, missing testing records and out-of-specification (OOS) investigations) (21 CFR 211.188).\n\nIn your response, you acknowledge that you did not follow your investigation procedures and that many of your investigations were incomplete. You note that you revised your procedures and commit to conducting investigations “as thoroughly as possible.” You also state that the missing production and laboratory records are from 2021 and 2022, and deviations were opened for each occurrence discovered.\n\nYour response is inadequate because you did not address how you will ensure that investigations contain adequate root cause determinations, corrective action and preventive action (CAPA), and effectiveness checks. You failed to appropriately address the impact of missing records on the quality of the drug products already on the market. You also did not address how you will maintain completeness and accuracy of the records used for batch release and other quality review decisions despite changes or turnover within the QU.\n\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM070337.pdf.\n\nIn response to this letter, provide:\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\nA complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\nAn independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final QU decisions, and is fully supported by executive management.\n\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\nA comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include, but not be limited to, addressing the following:\n\no QU oversight of laboratory investigations\n\no Identification of adverse laboratory control trends\n\no Resolution of causes of laboratory variation\n\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\n\no Adequate scoping of each investigation and its CAPA\n\no Revised OOS investigation procedures with these and other remediations\n\n2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1)).\n\nYou failed to perform adequate identity testing on each component lot used to manufacture your OTC drug products. For example, your component identity testing did not include a limit test for diethylene glycol (DEG) and ethylene glycol (EG) on all lots of glycerin before use in the manufacture of your drug products. Identity testing for this and certain other high-risk drug components1 includes a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform adequate identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in manufacture of your drug products.\n\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\n\nIn your response, you commit to testing each lot of glycerin for the presence of DEG and EG, and all incoming lots in conformance with the USP monograph for glycerin. You also state that you revised your written procedure for testing of raw materials to include identity testing.\n\nYour response is inadequate because it lacks specificity regarding your plans to test each lot of each shipment of incoming components. Additionally, you did not consider a retrospective risk assessment for products on the market and within expiry for which you did not conduct adequate identity testing on the components. Without appropriate testing of components, you cannot ensure the quality and safety of your drug products.\n\nFDA cited a similar CGMP observation in a June 2017 inspection.\n\nIn response to this letter, provide:\n\nA commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing reserve samples of all lots of high-risk drug components used in the manufacture of your drug products. Alternatively, if a reserve sample of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\n\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificate of analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\n\nThe chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\n\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\nYou did not adequately demonstrate that your manufacturing processes are reproducible and controlled to consistently yield drugs of uniform character and quality. For example, you failed to adequately validate your manufacturing process for (b)(4). Specifically, for at least two lots, you adjusted the pH during the bulk phase testing using an unvalidated process. During the inspection, you confirmed that this process was not validated.\n\nIn your response, you state that for topical drug products, you “default to the established cosmetic regulations because the sample matrices of sunscreens more similarly follow cosmetic formulations.”\n\nYour response is inadequate. Following requirements for cosmetics does not satisfy the regulations for finished pharmaceuticals. You are responsible for assuring your manufacturing processes will consistently result in drug products meeting predefined quality attributes.\n\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately to ensure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality are necessary to ensure that you maintain a stable manufacturing operation throughout the product lifecycle.\n\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\n\nIn response to this letter, provide:\n\nA detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\n\nA remediation plan that better assures ongoing management oversight throughout the manufacturing lifecycle of all drug products. Provide a more data-driven and scientifically sound program that identifies sources of process variability, and assures that manufacturing operations meet appropriate parameters and quality standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, ensuring quality of input materials, determining the capability and reliability of each manufacturing process step and its controls, and vigilant ongoing monitoring of process performance and product quality.\n\nTimelines for completing process performance qualification studies on remediated processes for marketed drug products for which a state of control has not been adequately and fully established.\n\nQuality Systems\n\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit2 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nYour reply should refer to case # 669736 and include your FEI 3005574978. Send your electronic reply to ORAPHARM3_RESPONSES@fda.hhs.gov.\n\nAttention: Brian Nicholson, Compliance Officer\n\nU.S. Food and Drug Administration\n\nDivision of Pharmaceutical Quality Operations Division III\n\nIf you have questions regarding the contents of this letter, please contact Compliance Officer, Brian Nicholson at (630) 207-9337.\n\nSincerely,\n\n\u002FS\u002F\n\nJeffrey D. Meng\n\nProgram Division Director\n\nOffice of Pharmaceutical Quality Operations Division III\n\n_______________________\n\n1 Components with higher risk of DEG or EG contamination compared to other drug components.\n\n2 i.e., Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","Bell International Laboratories, Inc.","bell-international-laboratories-inc-669736-02152024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbell-international-laboratories-inc-669736-02152024","2026-10-26T08:08:02.894937+00:00","Closed Out","2024-03-05","669736","2026-03-12","Division of Pharmaceutical Quality Operations III","Mr. Mohammed Saremi","2026-08-20T00:15:19.747+00:00","UPS Next Day","2024-02-15",{"id":115,"raw":116,"subject":121,"body_html":122,"body_text":123,"firm_name":124,"letter_id":125,"created_at":42,"fei_number":19,"letter_url":126,"updated_at":127,"action_type":22,"case_status":23,"posted_date":128,"marcs_cms_no":129,"product_type":130,"closeout_date":19,"issuing_office":120,"recipient_name":131,"body_fetched_at":132,"delivery_method":133,"recipient_title":19,"reference_number":19,"action_taken_date":134,"medical_device_id":19,"response_letter_date":19},875,[117,118,119,120,121,13,13,13],"\u003Ctime datetime=\"2025-05-27T04:00:00Z\">05\u002F27\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-03-31T04:00:00Z\">03\u002F31\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdrg-instruments-gmbh-700918-03312025\">DRG Instruments GmbH\u003C\u002Fa>","Center for Devices and Radiological Health","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA) Adulterated Device","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jörg Schlöβer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>DRG Instruments GmbH\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Frauenbergstr. 18\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Marburg\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>35039\u003C\u002Fspan> \u003Cspan>Hassia\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Germany\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)@drg-diagnostics.de\"> (b)(6)@drg-diagnostics.de  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>March 31, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Schlöβer:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Marburg, Germany on November 4 through 7, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures in vitro diagnostic devices including the Salivary Cortisol ELISA (REF No. SLV-2930), the Salivary Testosterone ELISA, and the Salivary Cortisol ELISA RUO (REF No. SLV-2930R). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved Device Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has reviewed evidence collected during the inspection and your firm’s website and determined that the Salivary Cortisol ELISA (REF No. SLV-2930) and Salivary Cortisol ELISA RUO (REF No. SLV-2930R) are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). The Salivary Cortisol ELISA and Salivary Cortisol ELISA RUO are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce these devices into commercial distribution, with major changes or modifications to the intended use, without submitting a new premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\u003Cp>\u003Cu>Salivary Cortisol ELISA\u003C\u002Fu>\u003C\u002Fp>\u003Cp>You currently have clearance dated December 7, 2005, for a version of the Salivary Cortisol ELISA which was cleared under K051733 as a class II device under 21 CFR 862.1205 with the following indications:\u003C\u002Fp>\u003Cp>“An enzyme immunoassay for the quantitative in vitro diagnostic measurement of active free cortisol (hydrocortisone and hydroxycorticosterone) in saliva. Measurements of cortisol are used in the diagnosis and treatment of disorders of the adrenal gland.”\u003C\u002Fp>\u003Cp>However, as discussed in FDA’s Warning Letter dated September 19, 2017 issued to your firm, your firm has failed to submit a premarket notification submission to the Food and Drug Administration for significant changes that could significantly affect the safety or effectiveness of the device, as required by 21 CFR 807.81(a)(3)(i). As discussed in the 2017 Warning Letter, a new 510(k) is needed due to the use of a new monoclonal (mouse) antibody for the Salivary Cortisol ELISA. In addition, a new 510(k) is needed because of the change to the assay measuring range. As described in the FDA’s Decision Summary, the device that was reviewed and cleared by FDA under K051733 included 8 wells coated with rabbit anti-cortisol antiserum and had an assay measuring range of 0.537 - 80 ng\u002FmL. However, the package insert of the IVD-labeled Salivary Cortisol ELISA obtained during the 2024 inspection is described as containing microtiter wells that are coated with a monoclonal (mouse) antibody and the assay measuring range is described as 0.09 – 30 ng\u002FmL. The modified measuring range is narrower than the clinically relevant range. This change raises concerns that some patient samples with salivary cortisol higher than 30 ng\u002FmL may yield inaccurate results using the new assay which could place patients with normal cortisol levels at increased risk of misdiagnosis (e.g. elevated cortisol may be an indicator of Cushing Syndrome) or could lead to missed diagnosis of Cushing Syndrome if results are erroneously low. Such changes could significantly impact the safety and effectiveness of the device because such devices are often used in people with cortisol levels greater than 30 ng\u002FmL. Your firm was notified in the 2017 Warning Letter that the Salivary Cortisol ELISA devices manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated and that, as a result, FDA was taking steps to refuse entry of these devices into the United States, known as “detention without physical examination,” until these violations were corrected. To date, your firm has not received 510(k) clearance for your Salivary Cortisol ELISA devices that incorporate this significant change.\u003C\u002Fp>\u003Cp>\u003Cu>Salivary Cortisol ELISA RUO\u003C\u002Fu>\u003C\u002Fp>\u003Cp>The inspection revealed that your firm also markets and distributes the Salivary Cortisol ELISA RUO. Based on labeling collected during FDA’s inspection, the Salivary Cortisol ELISA RUO, like the Salivary Cortisol ELISA for in vitro diagnostic use, is designed to include monoclonal mouse antibodies and has an assay measuring range of 0.09 - 30 ng\u002FmL. Specifically, your firm's website www.drg-international.com describes the Salivary Cortisol ELISA RUO as “an enzyme immunoassay for the quantitative in vitro diagnostic measurement of active free cortisol (hydrocortisone and hydroxycorticosterone) in saliva.”\u003C\u002Fp>\u003Cp>Based on evidence obtained during the inspection and a review of your firm’s website, the Salivary Cortisol ELISA RUO appears intended for clinical diagnostic use instead of for research use only. Such evidence includes:\u003C\u002Fp>\u003Cul>\u003Cli>Your firm’s website includes product descriptions, images, and statements that suggest the Salivary Cortisol ELISA RUO device is intended for clinical diagnostic use. [https:\u002F\u002Fstore.drg-international.com\u002Fpc_product_detail.asp?key=2EAFBB068F3341EF8772F433DA7255B4]. For example:\u003Cbr>o A statement on your firm’s product page for the Salivary Cortisol ELISA RUO says that the “intensity of colour developed is inversely proportional to the concentration of cortisol in the patient sample.”\u003C\u002Fli>\u003Cli>Labeling collected during the inspection which your firm distributes with the Salivary Cortisol ELISA RUO device includes information that appears to conflict with RUO and suggests the device is actually intended for clinical diagnostic use despite the RUO labeling. For example:\u003Cbr>o The instructions for use that your firm distributes with the Salivary Cortisol ELISA RUO contains a specimen collection and preparation section that describes how samples should be collected from individuals (e.g. “Eating, drinking, chewing gums or brushing teeth should be avoided for 30 minutes before sampling.”) and gives directions on how saliva samples should be collected and over what time period to collect samples from individuals. The instructions for use also contain a Quality Control section which notes that “[a] statistically significant number of controls should be assayed to establish mean values and acceptable ranges to assure proper performance” and that users should ensure that assay results fit the established range of control materials or else be considered invalid. This type of language is typically included for IVDs that are intended for clinical diagnostic use, as this type of information is consistent with the prospective testing of patients and is not the type of information that is necessary for an assay in the laboratory research phase of development.\u003C\u002Fli>\u003Cli>A review of the customer records collected during the 2024 inspection shows that your firm sold and shipped Salivary Cortisol ELISA RUO to multiple companies in the business of performing clinical analysis. There is no indication that these companies also conduct research.\u003C\u002Fli>\u003Cli>Your firm’s website (last accessed March 11, 2025) https:\u002F\u002Fdrg-international.com\u002Fsalivary-elisa-kits\u002F describes the Salivary Cortisol ELISA RUO, along with other Salivary ELISA Kits, as having clear advantages, including:\u003Cbr>o “Simple, painless collection”\u003Cbr>o “Simple and patient-friendly measurement of hormone profiles”\u003Cbr>o “Can be performed also by patients”\u003Cbr>o “Easy sampling in babies and kids”\u003Cbr>o “Provides accurate, low level detection”\u003Cbr>o Clinical applications such as:\u003Cbr> “Diagnosis of systemic\u002Flocal conditions”\u003Cbr> Obstetrics &amp; Gynecology”\u003Cbr> “Drug Monitoring”\u003C\u002Fli>\u003Cli>Your firm’s website also provides a comparison of the Salivary Cortisol ELISA RUO to a reference test and states it provides “Industry Leading Accuracy with Kit Components Calibrated to Mass Spectrometry,” which implies that the Salivary Cortisol ELISA RUO is intended for clinical diagnostic use and not for research use only.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In addition, during the inspection, your firm provided to the FDA investigator copies of certification letters from certain customers of the Salivary Cortisol ELISA RUO as evidence that these customers were aware that they were only supposed to use these products for research purposes. However, your firm admitted no such certification letter was received from one customer. A review of these customers’ websites strongly suggests that these customers are engaged in clinical diagnostic testing. As such, your statements that Salivary Cortisol ELISA RUO is intended for research use only are inconsistent with the evidence obtained during the inspection and the statements on your firm’s website, and FDA has determined that your Salivary Cortisol ELISA RUO is intended for clinical diagnostic use.\u003C\u002Fp>\u003Cp>Your Salivary Cortisol ELISA RUO appears to be intended for the quantitative in vitro diagnostic measurement of active free cortisol (hydrocortisone and hydroxycorticosterone) in saliva. You were required to submit to FDA a 510(k) for this device, because either it is a new device (21 CFR 807.81(a)(1)) or, if your Salivary Cortisol ELISA RUO represents a change or modification from the device cleared in K051733, it has been significantly changed or modified in design, components, method of manufacture, or intended use (21 CFR 807.81(a)(3)). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>Separately, we also note that your firm’s website includes a tab called “FDA Cleared Tests” (https:\u002F\u002Fdrg-international.com\u002F) and lists several devices for which there is no record of a 510(k) clearance held by your firm. For example, a Thyroid Stimulating Hormone (TSH) assay for in vitro diagnostic use is included on your firm’s website. However, a review of our records indicates that DRG Instruments does not have a 510(k) for a TSH assay. FDA requests that you review those devices listed under the “FDA Cleared Tests” tab on your website and either provide FDA with evidence that those devices are legally marketed or take corrective actions to address any additional uncleared devices marketed on your website.\u003C\u002Fp>\u003Cp>Further, during our review of your firm’s website (https:\u002F\u002Fdrg-international.com\u002Fhybrid-xl\u002F) we also noted that your firm states that DRG Hybrid XL is “Now FDA Approved” but also separately indicates that the DRG Hybrid XL is “FDA exempt for Class I.” We request that you clarify this statement on your website because indicating that a class I 510(k) exempt product has been reviewed and approved by FDA could be misleading. We request that your firm address these two additional issues in your response to this Warning Letter.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation (QSR) Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This inspection also revealed that the devices manufactured in your facility are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820. We received a response from Ina Hairston, U.S. Agent, DRG Instruments GmbH and Head of Regulatory Affairs, DRG International, Inc. dated November 26, 2024 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). For example, CAPA No. 2024-14 was initiated July 1, 2024 due to a customer complaint of the low-level quality control for their Salivary Testosterone ELISA being invalid. However, your firm did not adequately investigate the cause of the nonconformity. Your firm confirmed the complaint by testing the remaining kits in inventory from two lots and found 21.3% (17 out of 80 bottles) of the low controls were out-of-specification (OOS). Your firm determined that the cause was due to the operator not washing the filling tube, nor discarding the first ten bottles, after switching from a higher to lower concentration of bulk solution, which were typical but not defined in the manufacturing procedure. Your firm's corrective action was to revise procedure aa-9131 to define a rinsing step and to require discarding of the first 20 bottles. However, the determined root cause of incomplete rinsing instructions does not demonstrate how such a lack of written procedures would reasonably be expected to result in 21.3% of retained low controls being OOS. Further, during the inspection, Mr. Polleichtner, Head of Quality Management &amp; Regulatory Affairs, indicated that there may be additional causes for the nonconformity and that your firm did not confirm that the operator failed to perform the rinse and discard step.\u003C\u002Fp>\u003Cp>The adequacy of the response dated November 26, 2024 cannot be determined at this time. Your firm has opened CAPA# 2024-22 and planned the following actions:\u003C\u002Fp>\u003Cul>\u003Cli>update of root cause analysis for CAPA 2024-14 by December 20, 2024;\u003C\u002Fli>\u003Cli>review of all open CAPAs and all CAPAs which actions are completed, but the effectiveness check is still pending regarding comprehensive root cause analysis by January 31, 2025; and\u003C\u002Fli>\u003Cli>update CAPAs identified to have inadequate root cause analysis to update the process of determining the root cause and affirm the root cause by February 28, 2025.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm should provide an update on the above actions, including evidence of implementation. Copies of revised procedures and evidence of training on new or revised procedures should also be provided. Additionally, your firm should provide a summary of the results of their retrospective review.\u003C\u002Fp>\u003Cp>2. Failure to adequately maintain records of complaint investigations that include required information, according to 21 CFR 820.198(e). For example, records of complaint investigations do not include required information, including any unique device identifier (UDI) or universal product code (UPC). Your firm's complaint records consistently did not include adequate contact information for the complainant, to include telephone number and address, and consistently did not include the Unique Device Identifier (UDI) code for the device which was the subject of the complaint. Specifically, complaint records for Complaint Nos. 47 and 49 do not list the complainant’s telephone number, complainant’s address, or the UDI code for the device.\u003C\u002Fp>\u003Cp>The adequacy of your firm's response dated November 26, 2024 cannot be determined at this time. Your firm has opened CAPA# 2024-24 and planned the following actions:\u003C\u002Fp>\u003Cul>\u003Cli>add UDI and contact information to all open complaint files by December 15, 2024;\u003C\u002Fli>\u003Cli>review of the complaint handling process and form regarding conformity with applicable regulations (EN ISO 13485, 21 CFR, IVDR) by December 15, 2024;\u003C\u002Fli>\u003Cli>file a change request based on finding(s) of complaint review process. At minimum, the requirement to provide the UDI\u002FUPC and complete customer contact information with every complaint is required by December 15, 2024;\u003C\u002Fli>\u003Cli>inform and provide immediate information to the complaint-handling personnel emphasizing the importance of recording complete information;\u003C\u002Fli>\u003Cli>review of Medical Device Single Audit Program (MDSAP) guidance documents, as these outline US-specific requirements, and are based on EN ISO 13485 by December 31, 2024;\u003C\u002Fli>\u003Cli>request implementation of gaps identified to the MDSAP guidance if applicable by January 10, 2025; and\u003C\u002Fli>\u003Cli>train revised documentation as required by January 31, 2025.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm should provide an update on the above actions, including evidence of implementation. Copies of revised procedures and evidence of training on new or revised procedures should also be provided.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Medical Device Reporting (MDR) Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that you have failed to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17. For example: during the inspection, your firm identified the document titled “Reporting to Regulatory Authorities (and recall), Document aa-8.2.3.1, Revision 1, undated,” as its written MDR procedure. After reviewing the procedure, the following deficiencies were noted:\u003C\u002Fp>\u003Cul>\u003Cli>There is no evidence that the procedure has been implemented. For example, there is no effective date for your firm’s MDR procedure.\u003C\u002Fli>\u003Cli>The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example:\u003Cbr>o The definition of the term “Reportable Event” in section 5 of your firm’s procedure only focuses on whether the device at issue would be likely to cause or contribute to a death or serious injury if the malfunction were to recur and does not include a consideration of whether a similar device marketed by your firm would be likely to cause or contribute to a death or serious injury if the malfunction were to recur, as required in 21 CFR 803.3(o)(2)(ii).\u003Cbr>o The procedure does not include instructions for how your firm will evaluate information about an event to make MDR reportability determinations in a timely manner.\u003C\u002Fli>\u003Cli>The procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the following are not addressed:\u003Cbr>o Instructions for how to obtain and complete the FDA 3500A form.\u003Cbr>o The circumstances under which your firm must submit an initial 30 days, supplemental or follow-up, 5-day report and the requirements for such reports.\u003Cbr>o How your firm will submit all information reasonably known to it for each event. Specifically, which sections of 3500A will need to be completed to include all the information found in your firm’s possession and any information that becomes available as a result of a reasonable follow-up within your firm.\u003C\u002Fli>\u003Cli>The procedure does not describe how your firm will address documentation and record-keeping requirements, as required by 21 CFR 803.17(b), including:\u003Cbr>o Information that was evaluated to determine if an event was reportable.\u003Cbr>o Documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable.\u003Cbr>o Systems that ensure access to information that facilitate timely follow-up and inspection by FDA.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm’s procedure includes references to annual certifications. We note that annual certifications are no longer required, and we recommend that all references to an Annual Certification be removed from your firm’s MDR procedure. See 65 Fed. Reg. 4112 (Jan. 26, 2000). Furthermore, the procedure includes references to submit paper MDR reports. Please note, paper reports are generally no longer accepted from manufacturers and importers. See 21 CFR 803.11(a). The manufacturer is generally required to electronically submit MDRs following its established electronic submission process. 21 CFR 803.11(a).\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response dated November 26, 2024, cannot be determined at this time. The response notes that your firm plans to update its MDR procedure to include a reportability determination process, add evaluation recording process, and conduct staff training. However, your firm did not provide documentation or evidence demonstrating the implementation of these corrective actions, as they are still ongoing.\u003C\u002Fp>\u003Cp>We note that a device is deemed to be misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), if there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, which includes adverse event reports required under 21 CFR Part 803, respecting the device.\u003C\u002Fp>\u003Cp>Given the serious nature of the violations of the Act, the Salivary Cortisol ELISA and the Salivary Cortisol ELISA RUO devices manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA is taking steps to refuse entry of these devices into the United States, known as \"Detention Without Physical Examination of Devices without Approved PMA's or IDE's and Other Devices Not Substantially Equivalent or Without a 510(k),\" until these violations are addressed. To remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and address the violation(s) described in this letter. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which should address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS case 700918 when replying. If you have any questions about the contents of this letter, please contact: Kimberly Mapp at Kimberly.mapp@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Courtney H. Lias, Ph.D.\u003Cbr>Director\u003Cbr>OHT7: Office of In Vitro Diagnostic Devices\u003Cbr>Office of Product Evaluation and Quality&nbsp;&nbsp;\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC:\u003Cbr>Ina Hairston\u003Cbr>U.S. Agent, DRG Instruments GmbH and\u003Cbr>Head of Regulatory Affairs, DRG International, Inc.\u003Cbr>\u003Cstrong>(b)(4)\u003C\u002Fstrong>@drg-international.com\u003C\u002Fp>\u003Cp>Mr. Simon W. Huang, Chief Executive Officer\u003Cbr>BioCheck, Inc.\u003Cbr>\u003Cstrong>(b)(4), (b)(6)\u003C\u002Fstrong>@biocheckinc.com\u003C\u002Fp>\u003Cp>Mr. Stephen A. Baliani, Comptroller\u003Cbr>DRG International, Inc.\u003Cbr>\u003Cstrong>(b)(4), (b)(6)\u003C\u002Fstrong>@drg-international.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJörg Schlöβer\n\nRecipient Title\n\nManaging Director\n\nDRG Instruments GmbH\n\nFrauenbergstr. 18\n\nMarburg\n\n35039 Hassia\n\nGermany\n\n(b)(6)@drg-diagnostics.de\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nMarch 31, 2025\nDear Mr. Schlöβer:\nDuring an inspection of your firm located in Marburg, Germany on November 4 through 7, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures in vitro diagnostic devices including the Salivary Cortisol ELISA (REF No. SLV-2930), the Salivary Testosterone ELISA, and the Salivary Cortisol ELISA RUO (REF No. SLV-2930R). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nUnapproved Device Violations\nFDA has reviewed evidence collected during the inspection and your firm’s website and determined that the Salivary Cortisol ELISA (REF No. SLV-2930) and Salivary Cortisol ELISA RUO (REF No. SLV-2930R) are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). The Salivary Cortisol ELISA and Salivary Cortisol ELISA RUO are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce these devices into commercial distribution, with major changes or modifications to the intended use, without submitting a new premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\nSalivary Cortisol ELISA\nYou currently have clearance dated December 7, 2005, for a version of the Salivary Cortisol ELISA which was cleared under K051733 as a class II device under 21 CFR 862.1205 with the following indications:\n“An enzyme immunoassay for the quantitative in vitro diagnostic measurement of active free cortisol (hydrocortisone and hydroxycorticosterone) in saliva. Measurements of cortisol are used in the diagnosis and treatment of disorders of the adrenal gland.”\nHowever, as discussed in FDA’s Warning Letter dated September 19, 2017 issued to your firm, your firm has failed to submit a premarket notification submission to the Food and Drug Administration for significant changes that could significantly affect the safety or effectiveness of the device, as required by 21 CFR 807.81(a)(3)(i). As discussed in the 2017 Warning Letter, a new 510(k) is needed due to the use of a new monoclonal (mouse) antibody for the Salivary Cortisol ELISA. In addition, a new 510(k) is needed because of the change to the assay measuring range. As described in the FDA’s Decision Summary, the device that was reviewed and cleared by FDA under K051733 included 8 wells coated with rabbit anti-cortisol antiserum and had an assay measuring range of 0.537 - 80 ng\u002FmL. However, the package insert of the IVD-labeled Salivary Cortisol ELISA obtained during the 2024 inspection is described as containing microtiter wells that are coated with a monoclonal (mouse) antibody and the assay measuring range is described as 0.09 – 30 ng\u002FmL. The modified measuring range is narrower than the clinically relevant range. This change raises concerns that some patient samples with salivary cortisol higher than 30 ng\u002FmL may yield inaccurate results using the new assay which could place patients with normal cortisol levels at increased risk of misdiagnosis (e.g. elevated cortisol may be an indicator of Cushing Syndrome) or could lead to missed diagnosis of Cushing Syndrome if results are erroneously low. Such changes could significantly impact the safety and effectiveness of the device because such devices are often used in people with cortisol levels greater than 30 ng\u002FmL. Your firm was notified in the 2017 Warning Letter that the Salivary Cortisol ELISA devices manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated and that, as a result, FDA was taking steps to refuse entry of these devices into the United States, known as “detention without physical examination,” until these violations were corrected. To date, your firm has not received 510(k) clearance for your Salivary Cortisol ELISA devices that incorporate this significant change.\nSalivary Cortisol ELISA RUO\nThe inspection revealed that your firm also markets and distributes the Salivary Cortisol ELISA RUO. Based on labeling collected during FDA’s inspection, the Salivary Cortisol ELISA RUO, like the Salivary Cortisol ELISA for in vitro diagnostic use, is designed to include monoclonal mouse antibodies and has an assay measuring range of 0.09 - 30 ng\u002FmL. Specifically, your firm's website www.drg-international.com describes the Salivary Cortisol ELISA RUO as “an enzyme immunoassay for the quantitative in vitro diagnostic measurement of active free cortisol (hydrocortisone and hydroxycorticosterone) in saliva.”\nBased on evidence obtained during the inspection and a review of your firm’s website, the Salivary Cortisol ELISA RUO appears intended for clinical diagnostic use instead of for research use only. Such evidence includes:\nYour firm’s website includes product descriptions, images, and statements that suggest the Salivary Cortisol ELISA RUO device is intended for clinical diagnostic use. [https:\u002F\u002Fstore.drg-international.com\u002Fpc_product_detail.asp?key=2EAFBB068F3341EF8772F433DA7255B4]. For example:\no A statement on your firm’s product page for the Salivary Cortisol ELISA RUO says that the “intensity of colour developed is inversely proportional to the concentration of cortisol in the patient sample.”\nLabeling collected during the inspection which your firm distributes with the Salivary Cortisol ELISA RUO device includes information that appears to conflict with RUO and suggests the device is actually intended for clinical diagnostic use despite the RUO labeling. For example:\no The instructions for use that your firm distributes with the Salivary Cortisol ELISA RUO contains a specimen collection and preparation section that describes how samples should be collected from individuals (e.g. “Eating, drinking, chewing gums or brushing teeth should be avoided for 30 minutes before sampling.”) and gives directions on how saliva samples should be collected and over what time period to collect samples from individuals. The instructions for use also contain a Quality Control section which notes that “[a] statistically significant number of controls should be assayed to establish mean values and acceptable ranges to assure proper performance” and that users should ensure that assay results fit the established range of control materials or else be considered invalid. This type of language is typically included for IVDs that are intended for clinical diagnostic use, as this type of information is consistent with the prospective testing of patients and is not the type of information that is necessary for an assay in the laboratory research phase of development.\nA review of the customer records collected during the 2024 inspection shows that your firm sold and shipped Salivary Cortisol ELISA RUO to multiple companies in the business of performing clinical analysis. There is no indication that these companies also conduct research.\nYour firm’s website (last accessed March 11, 2025) https:\u002F\u002Fdrg-international.com\u002Fsalivary-elisa-kits\u002F describes the Salivary Cortisol ELISA RUO, along with other Salivary ELISA Kits, as having clear advantages, including:\no “Simple, painless collection”\no “Simple and patient-friendly measurement of hormone profiles”\no “Can be performed also by patients”\no “Easy sampling in babies and kids”\no “Provides accurate, low level detection”\no Clinical applications such as:\n “Diagnosis of systemic\u002Flocal conditions”\n Obstetrics & Gynecology”\n “Drug Monitoring”\nYour firm’s website also provides a comparison of the Salivary Cortisol ELISA RUO to a reference test and states it provides “Industry Leading Accuracy with Kit Components Calibrated to Mass Spectrometry,” which implies that the Salivary Cortisol ELISA RUO is intended for clinical diagnostic use and not for research use only.\nIn addition, during the inspection, your firm provided to the FDA investigator copies of certification letters from certain customers of the Salivary Cortisol ELISA RUO as evidence that these customers were aware that they were only supposed to use these products for research purposes. However, your firm admitted no such certification letter was received from one customer. A review of these customers’ websites strongly suggests that these customers are engaged in clinical diagnostic testing. As such, your statements that Salivary Cortisol ELISA RUO is intended for research use only are inconsistent with the evidence obtained during the inspection and the statements on your firm’s website, and FDA has determined that your Salivary Cortisol ELISA RUO is intended for clinical diagnostic use.\nYour Salivary Cortisol ELISA RUO appears to be intended for the quantitative in vitro diagnostic measurement of active free cortisol (hydrocortisone and hydroxycorticosterone) in saliva. You were required to submit to FDA a 510(k) for this device, because either it is a new device (21 CFR 807.81(a)(1)) or, if your Salivary Cortisol ELISA RUO represents a change or modification from the device cleared in K051733, it has been significantly changed or modified in design, components, method of manufacture, or intended use (21 CFR 807.81(a)(3)). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nSeparately, we also note that your firm’s website includes a tab called “FDA Cleared Tests” (https:\u002F\u002Fdrg-international.com\u002F) and lists several devices for which there is no record of a 510(k) clearance held by your firm. For example, a Thyroid Stimulating Hormone (TSH) assay for in vitro diagnostic use is included on your firm’s website. However, a review of our records indicates that DRG Instruments does not have a 510(k) for a TSH assay. FDA requests that you review those devices listed under the “FDA Cleared Tests” tab on your website and either provide FDA with evidence that those devices are legally marketed or take corrective actions to address any additional uncleared devices marketed on your website.\nFurther, during our review of your firm’s website (https:\u002F\u002Fdrg-international.com\u002Fhybrid-xl\u002F) we also noted that your firm states that DRG Hybrid XL is “Now FDA Approved” but also separately indicates that the DRG Hybrid XL is “FDA exempt for Class I.” We request that you clarify this statement on your website because indicating that a class I 510(k) exempt product has been reviewed and approved by FDA could be misleading. We request that your firm address these two additional issues in your response to this Warning Letter.\nQuality System Regulation (QSR) Violations\nThis inspection also revealed that the devices manufactured in your facility are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from Ina Hairston, U.S. Agent, DRG Instruments GmbH and Head of Regulatory Affairs, DRG International, Inc. dated November 26, 2024 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). For example, CAPA No. 2024-14 was initiated July 1, 2024 due to a customer complaint of the low-level quality control for their Salivary Testosterone ELISA being invalid. However, your firm did not adequately investigate the cause of the nonconformity. Your firm confirmed the complaint by testing the remaining kits in inventory from two lots and found 21.3% (17 out of 80 bottles) of the low controls were out-of-specification (OOS). Your firm determined that the cause was due to the operator not washing the filling tube, nor discarding the first ten bottles, after switching from a higher to lower concentration of bulk solution, which were typical but not defined in the manufacturing procedure. Your firm's corrective action was to revise procedure aa-9131 to define a rinsing step and to require discarding of the first 20 bottles. However, the determined root cause of incomplete rinsing instructions does not demonstrate how such a lack of written procedures would reasonably be expected to result in 21.3% of retained low controls being OOS. Further, during the inspection, Mr. Polleichtner, Head of Quality Management & Regulatory Affairs, indicated that there may be additional causes for the nonconformity and that your firm did not confirm that the operator failed to perform the rinse and discard step.\nThe adequacy of the response dated November 26, 2024 cannot be determined at this time. Your firm has opened CAPA# 2024-22 and planned the following actions:\nupdate of root cause analysis for CAPA 2024-14 by December 20, 2024;\nreview of all open CAPAs and all CAPAs which actions are completed, but the effectiveness check is still pending regarding comprehensive root cause analysis by January 31, 2025; and\nupdate CAPAs identified to have inadequate root cause analysis to update the process of determining the root cause and affirm the root cause by February 28, 2025.\nYour firm should provide an update on the above actions, including evidence of implementation. Copies of revised procedures and evidence of training on new or revised procedures should also be provided. Additionally, your firm should provide a summary of the results of their retrospective review.\n2. Failure to adequately maintain records of complaint investigations that include required information, according to 21 CFR 820.198(e). For example, records of complaint investigations do not include required information, including any unique device identifier (UDI) or universal product code (UPC). Your firm's complaint records consistently did not include adequate contact information for the complainant, to include telephone number and address, and consistently did not include the Unique Device Identifier (UDI) code for the device which was the subject of the complaint. Specifically, complaint records for Complaint Nos. 47 and 49 do not list the complainant’s telephone number, complainant’s address, or the UDI code for the device.\nThe adequacy of your firm's response dated November 26, 2024 cannot be determined at this time. Your firm has opened CAPA# 2024-24 and planned the following actions:\nadd UDI and contact information to all open complaint files by December 15, 2024;\nreview of the complaint handling process and form regarding conformity with applicable regulations (EN ISO 13485, 21 CFR, IVDR) by December 15, 2024;\nfile a change request based on finding(s) of complaint review process. At minimum, the requirement to provide the UDI\u002FUPC and complete customer contact information with every complaint is required by December 15, 2024;\ninform and provide immediate information to the complaint-handling personnel emphasizing the importance of recording complete information;\nreview of Medical Device Single Audit Program (MDSAP) guidance documents, as these outline US-specific requirements, and are based on EN ISO 13485 by December 31, 2024;\nrequest implementation of gaps identified to the MDSAP guidance if applicable by January 10, 2025; and\ntrain revised documentation as required by January 31, 2025.\nYour firm should provide an update on the above actions, including evidence of implementation. Copies of revised procedures and evidence of training on new or revised procedures should also be provided.\nMedical Device Reporting (MDR) Violations\nOur inspection also revealed that you have failed to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17. For example: during the inspection, your firm identified the document titled “Reporting to Regulatory Authorities (and recall), Document aa-8.2.3.1, Revision 1, undated,” as its written MDR procedure. After reviewing the procedure, the following deficiencies were noted:\nThere is no evidence that the procedure has been implemented. For example, there is no effective date for your firm’s MDR procedure.\nThe procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example:\no The definition of the term “Reportable Event” in section 5 of your firm’s procedure only focuses on whether the device at issue would be likely to cause or contribute to a death or serious injury if the malfunction were to recur and does not include a consideration of whether a similar device marketed by your firm would be likely to cause or contribute to a death or serious injury if the malfunction were to recur, as required in 21 CFR 803.3(o)(2)(ii).\no The procedure does not include instructions for how your firm will evaluate information about an event to make MDR reportability determinations in a timely manner.\nThe procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the following are not addressed:\no Instructions for how to obtain and complete the FDA 3500A form.\no The circumstances under which your firm must submit an initial 30 days, supplemental or follow-up, 5-day report and the requirements for such reports.\no How your firm will submit all information reasonably known to it for each event. Specifically, which sections of 3500A will need to be completed to include all the information found in your firm’s possession and any information that becomes available as a result of a reasonable follow-up within your firm.\nThe procedure does not describe how your firm will address documentation and record-keeping requirements, as required by 21 CFR 803.17(b), including:\no Information that was evaluated to determine if an event was reportable.\no Documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable.\no Systems that ensure access to information that facilitate timely follow-up and inspection by FDA.\nYour firm’s procedure includes references to annual certifications. We note that annual certifications are no longer required, and we recommend that all references to an Annual Certification be removed from your firm’s MDR procedure. See 65 Fed. Reg. 4112 (Jan. 26, 2000). Furthermore, the procedure includes references to submit paper MDR reports. Please note, paper reports are generally no longer accepted from manufacturers and importers. See 21 CFR 803.11(a). The manufacturer is generally required to electronically submit MDRs following its established electronic submission process. 21 CFR 803.11(a).\nThe adequacy of your firm’s response dated November 26, 2024, cannot be determined at this time. The response notes that your firm plans to update its MDR procedure to include a reportability determination process, add evaluation recording process, and conduct staff training. However, your firm did not provide documentation or evidence demonstrating the implementation of these corrective actions, as they are still ongoing.\nWe note that a device is deemed to be misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), if there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, which includes adverse event reports required under 21 CFR Part 803, respecting the device.\nGiven the serious nature of the violations of the Act, the Salivary Cortisol ELISA and the Salivary Cortisol ELISA RUO devices manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA is taking steps to refuse entry of these devices into the United States, known as \"Detention Without Physical Examination of Devices without Approved PMA's or IDE's and Other Devices Not Substantially Equivalent or Without a 510(k),\" until these violations are addressed. To remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and address the violation(s) described in this letter. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which should address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS case 700918 when replying. If you have any questions about the contents of this letter, please contact: Kimberly Mapp at Kimberly.mapp@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely yours,\n\u002FS\u002F\nCourtney H. Lias, Ph.D.\nDirector\nOHT7: Office of In Vitro Diagnostic Devices\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC:\nIna Hairston\nU.S. Agent, DRG Instruments GmbH and\nHead of Regulatory Affairs, DRG International, Inc.\n(b)(4)@drg-international.com\nMr. Simon W. Huang, Chief Executive Officer\nBioCheck, Inc.\n(b)(4), (b)(6)@biocheckinc.com\nMr. Stephen A. Baliani, Comptroller\nDRG International, Inc.\n(b)(4), (b)(6)@drg-international.com","DRG Instruments GmbH","drg-instruments-gmbh-700918-03312025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdrg-instruments-gmbh-700918-03312025","2026-10-26T08:08:27.462903+00:00","2025-05-27","700918","Medical Devices","Jörg Schlöβer","2026-08-19T16:44:15.579+00:00","VIA Electronic Mail","2025-03-31",6,{"510k":137,"classification":138,"enforcement":139,"event":140,"event_backfill":141,"pma":142,"warning_letter":143},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]